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Abstract 
Non-randomized studies aim to reveal whether or not interventions are effective in real-life 
clinical practice and there is a growing interest in including such evidence in the decision-making 
process. We evaluate existing methodologies and present new approaches to using non-randomized 
evidence in a network meta-analysis (NMA) of randomized controlled trials (RCTs) when the aim 
is to assess relative treatment effects. We first discuss how to assess compatibility between the two 
types of evidence. We then present and compare an array of alternative methods that allow the 
inclusion of non-randomized studies in an NMA of RCTs: the naïve data synthesis, the design-
adjusted synthesis, the use of non-randomized evidence as prior information and the use of three-
level hierarchical models. We apply some of the methods in two previously published clinical 
examples comparing percutaneous interventions for the treatment of coronary in-stent restenosis 
and antipsychotics in patients with schizophrenia. We discuss in depth the advantages and 
limitations of each method and we conclude that the inclusion of real-world evidence from non-
randomized studies has the potential to corroborate findings from RCTs, increase precision and 
enhance the decision-making process.  
Keywords: observational studies; observational evidence; observational data; multiple 
treatments meta-analysis; mixed treatment comparison; cohort studies. 
 
1 Introduction 
Pairwise and network meta-analyses (NMAs) are often limited to synthesizing evidence from 
randomized controlled trials (RCTs). NMAs frequently disregard evidence from non-randomized 
studies (NRSs) because the authors assume estimates of relative treatment effects are more likely to 
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be biased, especially when confounding has been inadequately addressed. When non-randomized 
evidence is included in an NMA, this amplifies concerns about transitivity and consistency assumed 
by the method, and fears that results may be very precise, yet biased. But interest in including NRSs 
in the NMA synthesis and decision-making process is growing [1–5]. Although RCTs are 
considered the most reliable source of information on relative treatment effects, their strictly 
experimental setting and inclusion criteria may limit their ability to predict results in real-world 
clinical practice [6]. NRS-based estimates of treatment effects may complement evidence provided 
by RCTs, and potentially address some of their limitations. However, less than 4% of the NMAs 
published until the end of 2012 included at least one non-randomized study (10 out of 261 identified 
NMAs) [7]. 
Expert opinion is required to formulate quantitative statements about the amount of bias 
propagated by non-randomized studies in a body of evidence [8]. A recent review summarized 
methods that account for potential bias from non-randomized evidence in a pairwise meta-analysis 
[9]. These include an additive bias model that accounts for both external and internal biases in 
studies [10]; the confidence profile method [11]; likelihood adjustments [12]; and, multiple-bias 
models [13]. Schmitz et al. [14] propose three different methods to combine data from different 
study designs in an NMA: ‘naïve’ pooling; use of non-randomized evidence as prior information; 
and, a three-level hierarchical model.  
In this paper we present statistical methods for combining randomized and non-randomized 
evidence in an NMA and we discuss their merits and limitations. We confine ourselves to the case 
where NMA is used to infer about the relative effects of health interventions. To this end, we 
consider only comparative non-randomized studies that aim to estimate relative treatment effects. 
These include observational studies as well as comparative clinical trials that do not employ 
randomization.   
2 Description of the motivating examples  
2.1 Percutaneous interventions for the treatment of coronary in-stent restenosis  
A previously published NMA synthesized aggregate data from 28 published RCTs (5914 
patients) that compared 8 different percutaneous interventional strategies for the treatment of 
coronary in-stent restenosis [15]. The follow-up in the included studies ranged from 6 to 60 months 
after the indexed intervention and several clinical outcomes were considered; we focus on the 
dichotomous outcome ‘target–lesion revascularization’ (TLR). Results were synthesized using the 
odds-ratio (OR).   
In addition to the RCTs, we identified data from 6 NRSs that provide evidence about TLR on 5 
interventions. The studies included a total of 1113 patients in 14 different cohorts. The network is 
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depicted in panel A, Figure 1. Detailed information about the included NRSs can be found in 
Section 4 of the Appendix. 
2.2 Antipsychotic drugs in schizophrenia  
The randomized evidence in this example consists of aggregate per-arm data from 167 RCTs 
(36871 patients) which compared 15 antipsychotic drugs and placebo in patients diagnosed with 
schizophrenia [16]. Change in symptoms (efficacy) was measured 4-12 weeks after randomization, 
based on the brief psychiatric rating scale (BPRS) or the positive and negative syndrome scale 
(PANSS). We use the standardized mean difference (SMD) to synthesize data. Using SMD as the 
effect measure enables the meta-analysis of studies that employ different scales, and it was also 
used in the original analysis [16]; researchers should note, however, that the use of SMD may be 
problematic under circumstances [17]. Study-level information was available for participant’s mean 
age and duration of illness. 
Non-randomized evidence consists of IPD from a large observational study (SOHO, 
Schizophrenia Outpatient Health Outcome) with 8873 adult patients from 10 European countries, 
who were treated with five different antipsychotics during a 3-year time frame [18]. Short-term 
change in symptoms was measured at three months, based on the Clinical Global Impression scale 
(CGI). The network is depicted in panel B, Figure 1. Because we have signed non-disclosure 
agreements with our industry partner who provided the observational data we use in this example, 
we code treatments as 1-16. 
 [INSERT FIGURE 1] 
3 Statistical methods 
We present the methods assuming that relative treatments from non-randomized evidence have 
been estimated using valid epidemiological and statistical methods that aim to minimize bias if 
possible. An overview of such methods can be found in Faria et al. [3]. When considering the 
inclusion of NRS for which IPD are not available, extra caution is warranted as the aggregated 
reported effect estimates may originate from suboptimal analyses. In any case, the quality of the 
evidence provided by the identified NRSs needs to be critically appraised. The recently proposed 
ROBINS-I tool can be used to evaluate the risk of bias in estimates obtained from studies that did 
not use randomization [19]. If the identified NRSs are believed to have a very high risk of selection 
bias their inclusion in NMA would be difficult to defend.  
None of the NRSs about the effects of percutaneous interventions for coronary in-stent restenosis 
provided IPD. To estimate the SMDs for the antipsychotics from IPD in SOHO we use regression 
adjustment analysis since there was enough overlap between the distributions of patient 
characteristics across treatment groups [3]. After consulting with expert psychiatrists to indicate 
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important patient-level covariates the SMDs from the non-randomized data were adjusted for 
baseline severity of the illness, age, gender and duration of illness.    
 In Section 3.1 we discuss the standard NMA model and fix notation. In Section 3.1, we describe 
methods for identifying possible discrepancies between randomized and non-randomized evidence. 
In Section 3.3, we present methods for synthesizing the two sources of evidence, assuming that no 
important differences have been found between them. We also describe the similarities and 
differences between the methods. Additional details for all models can be found in the Appendix. 
3.1 Standard NMA model with aggregated data 
The usual hierarchical, random-effects (RE) NMA model [20, 21] synthesizes data from all 
available studies to estimate the summary treatment effect, , and the heterogeneity standard 
deviation of the random effects, ,	for each treatment comparison X vs. Y. Assume that for a two-
arm XY study  we observe the relative treatment effect 	, along with a standard error, 
	. The 
model is then written as: 
	~(	, 
	
 ) 
	~( , 
 ) 
(1) 
We assume consistency, i.e.  =  −  for any choice of treatments X, Y and Z. This 
reduces the number of parameters and sets it equal to the number of treatments in the network 
minus one. Choosing treatment A as the reference, it is sufficient to estimate  for all treatments 
 ≠ ; these are called the basic parameters. All other treatment effects can be obtained as linear 
combinations of the estimated . Treatments can be ranked by any measure that summarizes the 
overlap between the estimated distributions of  [22]. An assumption commonly employed to 
facilitate the estimation of the heterogeneity parameters is to assume  =  for all treatments X 
and Y [23]. We use this assumption throughout this article for simplicity, although it is not 
necessary for any of the methods discussed below. For the inclusion of multi-arm studies the model 
described above is expanded to allow for both within and between-study correlations of the 
observations by using multivariate distributions. For a comprehensive review of standard NMA 
methodology, we refer the reader to our recent publication [24].  
3.2 Assessing the agreement within and across randomized and non-randomized evidence 
An NMA of RCTs should be internally consistent: information from direct and indirect sources 
of evidence for each treatment comparison should agree. The presence of inconsistency can be 
tested statistically [25] and any disagreements could be explored in subgroup analysis or network 
meta-regression. In the presence of large unexplained inconsistency NMA may be inappropriate. If 
no substantial inconsistencies are found in the NMA of RCTs one can proceed with the evaluation 
of the agreement between randomized and non-randomized evidence. Disagreements between 
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randomized and non-randomized evidence might be due to confounding in the non-randomized 
evidence, important differences in treatment effect modifiers across treatment groups of the NRSs, 
systematic differences in the definition of treatments between experimental and real-world settings 
(e.g. differences in dosages, modes of administration, adherence, etc.) or differences in patient 
characteristics. Inclusion criteria in RCTs are usually strict, so patients included in randomized 
studies may systematically differ from patients included in studies of real-world clinical settings. 
Examination of differences between direct and indirect evidence can be formalised by graphical 
and statistical comparison of the following information for each pairwise comparison XY: 
i. direct randomized evidence, from XY randomized trials; 
ii. indirect randomized evidence for XY, from the network, after excluding all direct XY 
studies; 
iii. direct non-rand mized evidence, from NRSs that include X and Y treatment arms.  
iv. indirect, non-randomized evidence.  
The four sources of evidence are independent and they can be formally compared with statistical 
tests. The tests for inconsistency are however low-powered and the usefulness of formal statistical 
inference will be limited [26]. Note that differences between (i) and (ii) correspond to the notion of 
inconsistency in NMA [27].  
Another, informal way to infer about agreement between randomized and non-randomized 
studies is to compare the estimated heterogeneity parameters between the two different datasets.  If 
NRSs are very different from RCTs, their inclusion into the network shall lead to an important 
increase in the heterogeneity parameter.  
If researchers identify a source of disagreement between randomized and non-randomized 
evidence they can perform analyses that account for it and improve comparability across the 
different sources of evidence. Cooper et al. [28] and Salanti et al. [29] presented a general network 
meta-regression framework for including study-level covariates in an NMA. We discuss network 
meta-regression models in more detail in Section 1 of the Appendix. Concerns about limited power 
and ecological bias are just as relevant in network meta-regression as in conventional meta-
regression. Additionally, using network meta-regression in practice might prove to be difficult or 
even completely infeasible, e.g. if there is no usable information on important study-level 
covariates. Other models beyond network meta-regression might be useful in addressing specific 
sources of heterogeneity and inconsistency. Differences in the definitions of the treatments could be 
explicitly modelled using previously presented approaches [30, 31]. When there are differences in 
the way that the outcomes are measured or reported (e.g. at different time points or using different 
scales), multiple outcomes NMA could be employed [32–34].  
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Researchers should note that even in the case of agreement between randomized and non-
randomized evidence it may be inappropriate to perform a joint NMA. Epidemiological assessment 
of the compatibility of the various sources of data should always be performed by a content expert 
before undertaking any form of joint synthesis. The identified NRSs need to be examined on 
whether or not they are sufficiently similar in terms of population, intervention, comparator and 
outcomes (PICO) with the ones specified in the research question that the review is aiming to 
answer [2]. When a NRS is deemed to be incompatible with the specific aims of the research 
question it should be excluded from all analyses, irrespective of whether its findings happen to 
agree with those from the RCTs.    
3.3 Methods for combining randomized and non-randomized evidence 
If the NMA of RCTs is consistent and provided that there is no evidence of substantial 
disagreement between the randomized and the (adjusted) non-randomized evidence, synthesis of 
data is warranted. Below we outline different approaches to synthesis and summarize their basic 
characteristics in Table 1. We distinguish three main methodological approaches: (A) synthesis of 
non-randomized and randomized studies where information from NRSs is manipulated to reflect 
confidence in the study findings; (B) constructing informative prior distribution from the non-
randomized evidence and subsequently use it in the NMA of RCTs; (C) a three-level hierarchical 
model, where one level of the model accounts for differences in RCT and NRS designs.  
Before embarking on these adjusted analyses investigators can obtain an initial insight of the 
effect of including NRSs in the network by synthesizing all data from all studies (‘naïve’ analysis) 
[14]. 
A. The ‘Design-adjusted’ evidence synthesis 
This approach synthesizes randomized and non-randomized studies, after adjusting the mean 
effect sizes and/or the variance of the latter. In a two-armed non-randomized study  the point 
estimate is shifted by 	, where 	 is a bias term. The variance of the mean effect is also inflated 
(divided by a factor 	 , with 0 < 	 < 1),	 so that the study’s weight in the meta-analysis 
decreases. The investigator must define not only values for each set of 	 and but also the direction 
of bias; that is which treatment is assumed to be ‘favored’.  The standard NMA model of Equation 
(1) is modified as follows: 
	~(	 + 	 ,

	

	
) 
	~(, 
 ) 
For a multi-armed study  with 	 treatment groups a bias vector  	with 	 − 1 elements needs 
to be specified, along with 	 to inflate the within-study variance-covariance matrix of the 
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observations.  Estimation of heterogeneity variances can be performed as usual in NMA, e.g. using 
likelihood methods, the methods of moments or within a Bayesian framework. The parameters 	 or 
	 	can be set equal to fixed values or can be treated as random variables within a Bayesian 
framework. A Bayesian approach offers maximum flexibility and would allow us to assign prior 
distributions to 	 or 	. Note that if a prior distribution is assigned to 	 then there is no need to do 
any additional down-weighting using 	, since the additional uncertainty incorporated in 	 will 
result to a down-weighting of study .  These prior distributions can be specified to reflect potential 
deficiencies in the non-randomized studies. For example, we may assign a prior for 	 	centered to 
values above 0.5 or even close to one to a well-conducted NRS with low or moderate risk of bias 
and PICO characteristics that are relevant to the research question. In contrast, we could assign a 
distribution for 	  that is centered at low values below 0.5 or close to 0 to a NRS of high risk of 
bias or a NRS that does not quite address the research question. Alternatively, 	 or 	  can be 
treated as random variables exchangeable across the included NRSs [35]. In the presence of 
discrepancies between NRSs and RCTs and if 	  are treated as random variables, their posterior 
will be centered around smaller values limiting the effect of the NRSs [36].  
Even though NRSs are generally considered to be at higher risk of bias [1], it may be hard to 
predict the direction (and also the magnitude) of possible biases in treatment effects [37–41], and 
this, in turn, makes it hard to pinpoint values for 	 and 	 . Biases in estimates of relative effects 
from NRSs may also depend on the method used to obtain them. Different methods used to estimate 
relative treatment effects from a NRS could give different results, making it harder to quantify 
potential biases. We recommend that researchers vary the amount of confidence they place on the 
non-randomized evidence by varying the value of 	 , and thus gauge the effect of non-randomized 
evidence on the model estimates. Setting all 	 ≈ 0 corresponds to an NMA of only RCTs. Setting 
larger values 	  places more confidence in non-randomized estimates. Setting all 	 = 1 is 
equivalent to the naïve model described above, where results from the NRSs are taken at face value. 
We do not recommend using values 	 > 1, which place more confidence on the NRSs.  
Eliciting expert opinion methods is needed to provide a range of plausible values for 	 and 	. 
Turner et al. [8] discuss how to elicit expert opinion regarding the bias parameters, and how to pool 
information from different experts. We previously described another method that can be used to 
pool expert opinion for a parameter ranging from 0 to 1 (such as 	) which is based on beta 
distributions [32]. In this method each expert opinion can be weighted according to the expert’s 
experience in the field. An approach alternative to expert opinion is to use information from 
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previously published meta-epidemiological studies (e.g. Anglemyer et al. [41]) using a model such 
as the one presented by Welton et al. [42]. 
B. Using non-randomized evidence as prior information 
Most NMAs with RCTs are done within a Bayesian framework [7], and non-informative priors 
are typically assumed for all basic parameters . In the presence of non-randomized evidence, 
however, these priors could be informative. The analysis is performed in two steps. First, a meta-
analysis (or an NMA, if possible) uses the non-randomized evidence to estimate mean relative 
treatment effects for some (or all) of the basic parameters. The (posterior) distributions estimated in 
this first step can be ‘adjusted’ for bias (by adding a bias parameter β to the mean and dividing the 
variance by w). Then these distributions are used in a second step as prior distributions for (some, or 
all of) the basic parameters of the NMA model which includes only RCTs. There are three different 
ways to construct informative priors. Expert opinion is needed for each one of them, for setting the 
values needed to adjust NRS.  
The first approach is to start by synthesizing non-randomized evidence to estimate ̂
%&' with a 
corresponding variance ()
%&'. This estimated variance ()
%&' incorporates both the sampling error 
and heterogeneity, so that the distribution (̂
%&', ()
%&') corresponds to the so-called ‘predictive 
distribution’ [43]. Then, down-weighting of the non-randomized evidence is achieved by 
assuming		~(̂
%&' + *, ()
%&'/), where * is a comparison-specific bias parameter 
and 0 <  < 1 is an inflation factor that quantifies the confidence to be placed in the non-
randomized evidence for AX [14]. The model can be extended to incorporate uncertainty in these 
two parameters by assigning	an informative prior distribution to * or to  (but not both). When 
the 	parameters are assumed to be random, their posterior distribution depends on the agreement 
between the sources of evidence. When randomized and non-randomized evidence disagree,  will 
obtain smaller values and decrease the impact of the non-randomized evidence on the pooled 
estimates. Setting all * = 0 and  = 1 corresponds to placing full confidence in the non-
randomized evidence; in such a case, and under the fixed-effect (FE) assumption, approach B 
becomes equivalent to a FE naïve analysis. Note that if some of the NRSs are multi-armed the 
corresponding estimates on basic parameters will be correlated. In such cases, we need to use 
multivariate prior distributions. For example, an A versus X versus Y non-randomized study will 
provide information on ,  and the corresponding variance-covariance matrix; these can be 
used to formulate a bivariate normal prior distribution on the two basic parameters.  
Another method for constructing the prior is to use the exact likelihood of the non-randomized 
data. The evidence provided by NRS 	can be down-weighted by raising the likelihood to a power 
0 ≤ -	 ≤ 1; this corresponds to the power-prior originally proposed by Ibrahim and Chen [44, 45]. 
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Dividing the variance by 	  (approach A) can be seen as a special case of the power prior method, 
where a study-specific power -	 	is chosen for the likelihood of each study. In the special case of 
normally distributed data, approach A and the power prior approach are equivalent: -	 	 corresponds 
to 	.  
Α third alternative approach is to use a mixture of priors [46, 47]. The prior distribution consists 
of two parts; an informative prior formed by the predictive distribution as described above, and a 
flat (uninformative) prior. A factor 0 ≤ . ≤ 1 controls the amount of information drawn from the 
informative part of the prior, and thus controls the contribution of non-randomized evidence to the 
final results. For the special case when normal distributions are used for both the informative and 
the uninformative parts of the prior, we can calculate how the mixture parameter . relates to the 
variance inflation parameter . More details can be found in Section 3 of the Appendix. 
 The major difference between approaches A and B is the way that heterogeneity is accounted 
for in the analysis. In approach A, there is a single heterogeneity parameter for the relative 
treatment effects estimated in RCTs or NRSs. Approach B assumes two different heterogeneity 
parameters; one for NRSs and one for the RCTs. This is relevant because NRSs may tend to be 
more dissimilar than RCTs. When few NRSs are available (as in the example of antipsychotics), 
researchers cannot use a random-effects meta-analysis to formulate a predictive prior distribution, 
unless they make some assumption about heterogeneity. For example, the estimate from the naïve 
analysis or empirical data can use used to construct the predictive distributions. One important 
limitation of using NRSs to formulate prior distributions is that it precludes the option to explore 
differences with RCTs in a network meta regression model. 
C. Three-level hierarchical models 
Three-level hierarchical models are suitable to synthesize data from studies with many different 
designs (e.g., different RCT designs, controlled trials, cohort studies, case-control, etc.) [14, 48, 49]. 
We present three different realizations of a hierarchical model for NMA. The main difference 
between them is the way the analysis incorporates the consistency assumption. We denote the 
various study designs with /. At the first level, each study is analyzed separately to obtain estimates 
of the relative effects of the treatments that are compared in the study. 
Model C.1 
At the second level in this model, NMA (including the consistency equations) is used to 
synthesize studies of the same design to obtain design-specific NMA estimates for the basic 
parameters and the heterogeneity variance 0
.  
0	~(0	 , 
0	
 ) 
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0	~(10 − 10, 0
) 
The model can be used to include multi-arm studies using standard NMA methodology. Although 
we assume a single heterogeneity parameter within each design for simplicity, the model can be 
written using comparison-specific heterogeneities. At the third level, the basic parameters are 
assumed to be exchangeable across designs, which accounts for possible design-level heterogeneity, 
234
 , i.e. 10~(* , 234
 ), 10~(*, 234
 ), etc. For the case of two different study designs 
(RCTs and NRSs), setting 234
 = 0 renders the model equivalent to approach B (with  = 1	and 
* = 0	for all basic parameters). Note that model C.1 requires an NMA to be performed for each 
study design using a subset of the same set of basic parameters. This might be infeasible in practice 
(see Section 4 of the Appendix for an illustration. Model C.1 cannot be used in such cases). 
Model C.2 
At the second level we perform a series of pairwise, design-specific meta-analyses to obtain 
summary effects for all available treatment comparisons. The meta-analyses do not impose the 
consistency equations, but assume a common heterogeneity 0
 for all treatment comparisons within 
design /, which corresponds to the ‘unrelated mean effects model’ described by Dias et al. [50]:  
0	~(0	 , 
0	
 ) 
0	~(10 , 0
) 
If the common heterogeneity assumption is relaxed the model corresponds to a series of 
unrelated pairwise meta-analyses.  
At the third level, a random-effects NMA (with heterogeneity 234
 ) uses the consistency 
equations to synthesize estimates from the second level, i.e. we assume that 10~(* −
, 234
 ). Model C.2 is problematic when the dataset contains multi-arm trials, because different 
parameterizations of the unrelated mean effects model can result into different estimates 0  [50]. 
Model C.3 
At the second level an NMA is performed separately per design. This imposes consistency 
exactly as in model C.1. Again the heterogeneity within each design can be assumed to be common, 
or different parameters can be assigned to different comparisons. At the third level, the estimates of 
the basic-parameters and their variance-covariance matrix from the design-level NMAs are 
synthesized in a new NMA, where they are treated as multi-arm studies and consistency equations 
are again imposed. This model assumes consistency twice – once within, and once across designs. 
At the third level, the common heterogeneity parameter of the NMA is 234
 . Note that this model 
does not require all NMAs at the second level to estimate a subset of the basic parameters.  
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In any three-level hierarchical model the estimates from each study can be adjusted if 
appropriate, by shifting the mean and/or inflating the variance. Alternatively, evidence from each 
design can be down-weighted by inflating the variance of the estimates obtained at the second level. 
A major constraint in applying models C.1, C.2 and C3 is the availability of data from many 
different designs. Using an informative prior distribution for 234
  will improve estimates in the 
presence of few designs. This prior distribution could be formulated using expert opinion that takes 
into account the expected dispersion of results in different designs. Alternatively, information of 
meta-epidemiological studies that include information on multiple types of designs (e.g. RCTs, 
registries, pragmatic trials, observational studies etc.) could be used to form empirical prior 
distributions. 
3.4 Comparison of models 
The three approaches presented here have similarities and, under specific circumstances, can 
lead to identical or equivalent statistical models. Frequentist and Bayesian implementation of model 
A with non-informative or weakly informative priors and the (necessarily Bayesian) Model B 
should give similar yet not identical results. Differences between frequentist and Bayesian methods 
are likely to result primarily from the estimation of heterogeneity parameters (which is assumed to 
be a random variable within the Bayesian context), as any prior distribution for these types of 
parameters tends to be informative. It is also possible to modify the models’ characteristics, and to 
combine their distinctive features. For example, the effect sizes and variances of each NRS can be 
adjusted separately (as in model A) before using the three-level hierarchical model (C). Table 1 
offers guidance for choosing a model appropriate to apply in practice.  
[INSERT TABLE 1] 
4 Estimating the influence of the non-randomized evidence in the results from NMA 
Once the non-randomized evidence is synthesized jointly with the randomized evidence, the 
credibility of the final summary treatment effects needs to be evaluated. The evaluation should 
consider, among other, the risk of bias in the included studies. One cannot exclude the possibility of 
residual bias due to the inclusion of NRSs, even after excluding studies with high risk of bias or 
adjusting effect estimates for relevant confounders. Although bias adjustments are usually 
considered only for the case of NRSs, RCTs may also suffer from design deficiencies that may bias 
their results. Calculating the relative contributions of the various sources of evidence is important 
when forming a critical appraisal of the NMA results. This is achieved by taking into account the 
various design limitations as well as how much each design is contributing to the final NMA 
treatment effect estimates [51]. 
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It has been shown that each relative treatment effect estimated in an NMA can be expressed as 
the weighted average of a set of direct pairwise meta-analyses [52]. The weights of pairwise meta-
analyses in estimating each NMA treatment effect form the ‘hat matrix’ [52], and can also be 
presented in a contribution matrix [51]. Since each direct meta-analysis is the weighted average of 
study-specific results, the contribution matrix can be updated to show the percentage contribution of 
each study in the pooled NMA estimates. A recent application of this approach can be found in 
[53].  The study contributions can be grouped to present how much evidence the randomized and 
non-randomized studies finally contribute to the NMA results. The contribution matrix for an NMA 
can be obtained with available software, like the netmeta command in R [54] or the netweight 
command in Stata [55]. 
Contributions can be readily calculated in approach A when the model is fitted in a frequentist 
setting, and can provide a percentage contribution of each study. A contribution matrix could also 
be estimated in approach C.  In model C.1 it is possible to calculate the contribution each design 
makes to each meta-analysis of basic parameters at the third level, and then sum these contributions 
within each design. For models C.2 and C.3 the contribution matrix of the NMA, which is 
performed at the third level (the design level), contains information on the effect of each design on 
the pooled summary effects. 
Calculating study contributions in approach B (and generally for models fitted in Bayesian 
setting) is not straightforward. A measure similar to a multivariate 5 statistic introduced by Jackson 
et al. can be used to estimate contributions (5&
 in [56]). In an NMA model, the ( − 1)67 root of the 
determinant of the variance-covariance matrix (denoted here as 8) measures the precision of the 
estimates for the basic parameters. The contribution of the non-randomized evidence can then be 
approximated by the relative decrease in 8 when priors with various weights are employed. For 
example, the model is fitted using uninformative prior, so that 8&9:	is based only on RCTs, and then 
8;<< is estimated using informative priors based on NRSs. Then, the contribution of NRS can be 
approximated with 5%&'
 = (8&9: −	8;<<)/	8&9:. 5%&'
  can also be used in models A and C (or any 
other similar model), but complications arise because the estimate for heterogeneity may change 
after NRSs are included and the 5%&'
  may acquire negative values for these models. Also, it might 
be resource intensive to use it to calculate the contribution of each individual study. 
5 Illustrative examples 
We used the network of the percutaneous interventions for the treatment of coronary in-stent 
restenosis to illustrate approach A, and we employed the network command in Stata [57, 58]. The 
network of antipsychotics for schizophrenia was used to illustrate approach B. The mean age and 
mean duration of illness of participants are important study-level effect modifiers, and we used 
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network meta-regression to include them in the analysis. Since estimating heterogeneity () in the 
non-randomized evidence is impossible in this example (there is only one NRS), we used the 
estimate from the naïve analysis to construct predictive distributions. To exemplify approach C we 
used the antipsychotics network, after assuming four different study categories; RCTs at low, 
moderate and high risk of bias (see Section 6 of the Appendix for more detail), and also the 
observational study. We then treated the groups as different designs. We used model C1 presented 
in Section 3.3 to synthesize the data. We fitted approaches B and C in OpenBUGS version 3.2.2 
[59, 60] (codes are provided in the Appendix). For all analyses we ran two chains that allowed for 
200.000 samples after a 100.000 burn-in period, and checked convergence with the Gelman and 
Rubin diagnostic. Initial values were automatically generated using the default OpenBUGS 
procedure.  
In order to assess compatibility between the various sources of evidence we first decomposed the 
randomized evidence into its direct and indirect components, and then compared them with the non-
randomized evidence. We used the network command in Stata, which implements the loop-
specific approach [61] and the node-splitting approach [27].  
5.1 Assessing the agreement within and across randomized and non-randomized evidence  
5.1.1 Percutaneous interventions for coronary in-stent restenosis 
In Figure 2 we present the relative treatment effects estimated from direct, indirect randomized 
and non-randomized evidence. For each treatment comparison the figure shows the treatment 
effects from the direct randomized evidence (from RCTs that compare the corresponding 
treatments), the indirect randomized evidence (from the network of RCTs after excluding direct 
evidence), the direct non-randomized evidence (from NRSs that compare the corresponding 
treatments) and the indirect non-randomized evidence (from the network of NRSs after excluding 
direct non-randomized evidence). Randomized and non-randomized evidence are in reasonable 
agreement for most treatment comparisons. However, for some comparisons (in particular DvsA, 
DvsC, EvsC and GvsB) there are considerable discrepancies The discrepancies in EvsC and DvsC 
are mainly driven by a single EC non-randomized study [62] whose results were very different from 
those in RCTs examining the same comparison. This might be due to chance or indicate important 
unaccounted confounding in the NRS and differences in the population, setting and interventions 
between the NRS and the RCTs.  
The heterogeneity standard deviation was estimated to be ̂ = 0.36 for the RCTs network and 
̂ = 0.45 for the naïve analysis. The loop-specific approach did not detect any inconsistencies in the 
RCTs network or in the combined RCTs and NRSs network. The node-splitting approach showed 
no inconsistencies in the RCTs network, but found inconsistency in the DvsA comparison in the 
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combined RCTs and NRSs NMA. This inconsistency is due to the difference in estimates coming 
from indirect randomized and direct non-randomized evidence as shown in Figure 2. Detailed 
results from these analyses are presented in Section 5 of the Appendix. 
In a real-life application, researchers would need to further explore these disagreements, 
scrutinizing the identified studies in order to make a judgment on whether or not it is appropriate to 
pool them in a single NMA. To further exemplify the methods, we assume that the identified 
differences are due to chance and we proceed into synthesizing the totality of the evidence in an 
NMA. 
[INSERT FIGURE 2]   
5.1.2 Antipsychotic drugs in schizophrenia 
Figure 3 presents the estimates for treatment comparisons for which both randomized and non-
randomized evidence is available. We detected some disagreement only for the 4v6 comparison.  
The confidence intervals of effects from direct randomized and non-randomized evidence overlap to 
some extent but there is a discrepancy between the estimates that correspond to indirect randomized 
evidence and the evidence from the single NRS. This might indicate that the adjustment of the non-
randomized data was insufficient (e.g., due to residual confounding). There is considerable 
heterogeneity in the five RCTs that make up the direct randomized evidence (5 = 71%, ̂ = 0.33), 
while the prediction interval is rather broad (-1.18, 1.23) and includes the estimate from the NRS. In 
such a case, heterogeneity in the RCTs that compare 4v6 should be fully explored.  
Comparing estimates from an NMA of the RCTs only with estimates from the naïve NMA also 
indicated that treatment effects are in agreement between the different sources. The precision of 
some treatment comparisons increased when non-randomized evidence were included in the 
network. For instance, the width of the credible interval was reduced by 27% for the 1vs15 
comparison. We compared the heterogeneity standard deviation before and after including the non-
randomized study and found no differences: ̂ = 0.08 (95% Cr.I. (0.04, 0.12)) for the RCTs-only 
network, and 0.09 (0.05, 0.12) for the naïve RCTs and NRS network. The loop-specific and the 
node-splitting approach did not provide any strong evidence of inconsistency either before or after 
adding the NRS to the network of RCTs (results are presented in Section 7.1 of the Appendix). We 
conclude that we found no evidence of important disagreement between randomized and non-
randomized summary effects and that synthesis of both sources is warranted.   
 [INSERT FIGURE 3] 
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5.2 Using the design-adjusted analysis (approach A) for the coronary in-stent restenosis example  
We employ approach A where we assume that estimates from each NRS are expected to be 
unbiased ( = 0), with an uncertainty reflected on w. However, we want to down-weight the NRS 
employing various scenarios for a common variance-inflation factor (), for all NRSs.   
Figure 4 shows the estimated relative treatment effects for all comparisons informed by both 
randomized and non-randomized studies for various values of confidence placed on NRSs. For 
some treatment comparisons (CvsA; DvsA; EvsA; GvsA) the inclusion of the NRSs in the network 
corroborated the findings of the NMA based on RCTs alone and increased the precision in the 
estimates. For three comparisons (DvsC; EvsD; GvsD) the inclusion of non-randomized evidence 
pulled the summary effect towards the non-effect line even for low values of . Such a result might 
potentially shed doubts on whether or not the difference in the efficacy of the corresponding 
interventions can be translated into difference of real-world effectiveness, and might have 
interesting clinical implications. However, these changes in the summary effect and their 
confidence intervals were not sufficient to change the treatment hierarchy estimated using the 
surface under the cumulative ranking line (SUCRA) [63] which remained unchanged with the 
various analysis models. Results can be found in Section 5 of the Appendix. 
In this example the NRSs accounted for 16% of the total sample size in the network. In the naïve 
analysis the contribution of NRSs was 20.3%. The contribution decreased to 19.0% for  = 0.8; 
16.5% for  = 0.5 and 10.3% for  = 0.2.   
 [INSERT FIGURE 4]  
5.3 Using non-randomized evidence as prior information (approach B) for the schizophrenia 
example 
In order to use the non-randomized evidence as prior information, we first needed to choose the 
basic parameters appropriately (see Section 2 of the Appendix on choosing the basic parameters). 
The single NRS compares treatments 1, 4, 5, 6, and 15 and consequently we could choose any of 
those treatments to be the reference treatment; here we chose treatment 1. We used the NRS to 
estimate a multivariate predictive distribution for the basic parameters 1vs4, 1vs5, 1vs6, and 1vs15, 
and we used the heterogeneity estimated from the naïve analysis (̂ = 0.09). We used a common 
variance inflation factor for these basic parameters to explore three different scenarios: 
~FG/H(0, 0.3), which places a low level of confidence in the non-randomized evidence; 
~FG/H(0.3, 0.7), which places a medium level of confidence; and ~FG/H(0.7, 1), which places 
a high level. The rest of the basic parameters were drawn from non-informative distributions, 
(0,100).  
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Estimates of the relative treatment effects are presented in Figure 5. For most treatment 
comparisons (1vs5, 1vs15, 4vs5, 4vs15, 5vs6, 5vs15 and 6vs15) the inclusion of the single NRS in 
the evidence-base confirmed the findings and increased precision of the estimates. As expected, 
treatment hierarchy was robust to the various prior options. Estimates of the model parameters and 
SUCRA values are presented in Section 7 of the Appendix.  
For the first scenario, 5%&'
  was calculated to be 4.7%; for the second scenario, it was 7%; and, 
for the third, it was 8.5%.  
[INSERT FIGURE 5] 
5.4 Using the three-level hierarchical model (model C1) for the schizophrenia example 
We assumed that the design ‘high RoB RCTs’ and the ‘NRS’ design have the same 
heterogeneity parameter denoted as 70I7, and that designs ‘low RoB’ and ‘moderate RoB’ pertain 
to  <JK&MJ23N;63. 
We used four different values for  ranging from 0 (NRS excluded from the analysis) up to 1 
(no down-weighting of the NRS). In Table 2 we present the model estimates only for the basic 
parameters which were informed by both randomized and non-randomized sources. Comparing to 
the results of approach B the most notable difference is the increased imprecision. This is because 
model C incorporates an additional source of variability in the model, i.e. the heterogeneity across 
designs. Another interesting finding is that NRS had a larger impact on results; for no down-
weighting ( = 1), 5%&'
  was calculated to be 14% (for the third scenario of model B in the previous 
section this was 8.5%). This increase of the contribution of NRS was because this study was the 
only source of information for one of the four available designs in the dataset. 
For  = 1 the heterogeneity standard deviations were estimated ̂70I7= 0.07 (0.01, 0.12) and 
̂<JK&MJ23N;63= 0.06 (0.003, 0.16). The estimate for the design-level heterogeneity was ̂234= 0.07 
(0.02, 0.13), indicating relatively small differences across different designs. These estimates did not 
materially change when we used different weighting schemes for the NRS. 
 [INSERT TABLE 2] 
6 Discussion 
In this article we discussed approaches for incorporating non-randomized evidence in an NMA 
of RCTs. These approaches should be employed after researchers have performed a formal 
assessment of the risk of bias and the applicability of the identified studies. This is needed in order 
to evaluate whether the inclusion of each study is sufficiently justified. We also argue that before 
performing a joint analysis of randomized and non-randomized evidence, researchers need to ensure 
the compatibility of the different pieces of evidence, for each treatment comparison. If studies are 
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deemed incompatible a priori (i.e. before comparing effect estimates across study designs), their 
inclusion in the NMA should not be considered. 
We grouped the available methods for combining randomized and non-randomized evidence in 
an NMA into three categories; the design-adjusted analysis, the use of informative prior 
distributions and the three-level hierarchical models. We do not recommend using the naïve 
approach as the main method of analysis, but it can be a useful starting point, and can provide 
insight about the effect of including non-randomized evidence in the analysis. The naïve approach 
can also be used to assess compatibility of randomized and non-randomized evidence, via 
monitoring changes in network heterogeneity and inconsistency before and after inclusion of non-
randomized evidence.  
The ‘design-adjusted’ approach extends the naïve approach by considering the design of the 
studies. The data from non-randomized studies are ‘shifted’ and down-weighted based on external 
opinion about their credibility. We recommend using this approach when resources allow for a 
separate assessment of bias for each non-randomized study. Using the non-randomized evidence to 
construct informative prior distributions for the basic parameters of the model is an elegant 
alternative for including non-randomized evidence in the NMA. A key difference with the design-
adjusted approach is in the estimation of heterogeneity, which is performed separately for RCTs and 
NRSs. This approach might be more intuitive for clinicians, since they typically have prior opinions 
about treatment effects based on their experience with patient follow-up, monitoring, and registries. 
Hierarchical models are more appropriate when data from studies of several different designs are to 
be synthesized and account for heterogeneity within and across designs. While the other methods 
assume that the underlying treatment effects are the same across designs, the three-level hierarchical 
models assume that the treatment effects are different – but exchangeable – across different types of 
studies.  
In our two illustrative examples we employed the design-adjusted approach (in-stent restenosis) 
and the prior-based approach (schizophrenia), with various degrees of confidence placed to the 
NRSs. For the in-stent restenosis network the inclusion of NRSs confirmed the findings of the 
RCTs-only analysis for most comparisons. For some of the comparisons results were shifted, 
indicating smaller differences in the outcome between the interventions even when low confidence 
was placed on the non-randomized evidence. For the schizophrenia example the inclusion of non-
randomized evidence did not materially impact on the conclusions of the analysis. Precision of the 
relative treatment effect estimates increased only slightly when we incorporated non-randomized 
evidence in the analysis, because the contribution of the single, although very large, non-
randomized study was small compared to that of 167 RCTs.  
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Whatever method researchers choose to employ they should keep in mind that it is difficult to 
predict the magnitude or direction of possible biases introduced by including NRSs in an NMA. We 
thus advise them to explore the effect of placing different levels of confidence in the non-
randomized evidence before they draw final conclusions. We also recommend that all results should 
be evaluated after considering the relative contribution of each source of evidence in the pooled 
estimates. This might be especially relevant for the case that NRSs are used to connect disconnected 
parts of the network of RCTs; on such occasions the connecting studies may acquire an unduly 
large contribution for (some) of the network estimates, even after severe down-weighting.   
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Table 1: Overview of the presented approaches for combining randomized and non-randomized evidence. Abbreviations: NMA=network meta-
analysis. RE= Random-effects. NRS= non-randomized study. RCT=randomized controlled trial 
 
Design-adjusted analysis 
(Approach A) 
Using informative priors 
(Approach B) 
Three-level hierarchical models 
(Approach C) 
Description 
All trials are included in the NMA. Estimates 
from each NRS are adjusted for possible bias 
and over-precision. 
Meta-analysis of RCTs using informative 
priors distributions formulated after meta-
analyzing all NRSs. 
Data is first synthesized by design and then the 
design-specific summary estimates are pooled in 
a joint (network) meta-analysis. 
How are NRS 
incorporated 
Each NRS can be adjusted separately, 
according to its features. Alternatively, 
common bias parameters can be assumed for 
all NRS. 
Between-design variability in treatment 
effect is ignored. 
The priors are shifted to account for bias 
and/or the variances are inflated to down-
weight estimates from NRSs. 
Between-design variability in treatment 
effect is ignored. 
Each NRS can be adjusted separately, according 
to its features, if resources allow. Or adjustment 
for bias can be performed collectively for each 
design, on the design-level estimates. 
Implementation 
Challenges 
Expert opinion is needed to choose 
appropriate values for wj and βj. 
Magnitude and directionality of bias in NRS 
may be hard to predict. 
Choosing basic parameters and formulating 
priors may be non-trivial for complex 
network structures in the NRSs. 
Estimating heterogeneity may be hard if 
few RCTs or NRSs are available. 
Impossible to include NRSs and RCTs in a 
joint network meta-regression. 
Estimating τdes either requires including several 
designs, or a strongly informative prior. 
Model C.1 requires meta-analyzing all designs, 
using a subset of the same basic parameters. 
Model C.2 is problematic in the presence of 
multi-arm studies 
Software 
considerations 
Easily implemented in all NMA software 
when fixed values for wj and βj are used. 
Can be implemented only in a Bayesian 
framework (e.g. OpenBUGS) 
Any software that implements hierarchical 
models 
Better to use 
when 
Should be preferred when resources allow 
inference about bias in each separate study. 
Use when it is infeasible to infer about bias 
in each study separately. 
Use when there are studies pertaining to 
multiple designs. 
Technical 
details 
The mean effect size in the jth  NRS can be 
shifted by a bias factor βj. The variance of the 
treatment effects can be inflated by dividing 
with a variance-inflation factor 0<wj<1. 
When wj=0, all NRS are excluded; when 
wj=1, no adjustment takes place. 
A RE-NMA of all NRSs is performed and 
the predictive distributions for the summary 
effects are used as priors for the basic 
parameters of the NMA of RCTs. 
First, data are meta-analyzed per design, using a 
design-specific heterogeneity parameter. 
Second, all design-specific estimates are 
synthesized to obtain an overall treatment effect 
that accounts for between-design heterogeneity. 
 
 
Page 24 of 58Statistics in Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
25 
 
 
Table 2: Estimated treatment effects and 95% credible intervals for the antipsychotics network, for 
basic parameters informed both by RCTs and NRS as estimated from model C1. Larger values of w 
correspond to larger down-weighting of the NRS.  
 Treatment comparison 
Variance inflation factor (w) 1v4 1v5 1v6 1v15 
0.0 
(RCTs only) 
0.04 
(-0.08, 0.16) 
-0.12 
(-0.26, 0.01) 
0.08 
(-0.08, 0.24) 
0.31 
(0.11, 0.50) 
0.3 
0.05 
(-0.04, 0.16) 
-0.12 
(-0.23, -0.01) 
0.05 
(-0.08, 0.18) 
0.26 
(0.10, 0.41) 
0.7 
0.06 
(-0.04, 0.16) 
-0.11 
(-0.22, -0.01) 
0.04 
(-0.08, 0.17) 
0.25 
(0.10, 0.40) 
1 .0 
(no down-weighting) 
0.06 
(-0.04, 0.16) 
-0.11 
(-0.22, 0.00) 
0.04 
(-0.08, 0.17) 
0.25 
(0.11, 0.41) 
 
 
 
Figure 1: Networks of evidence for A) percutaneous interventions for coronary in-stent restenosis, 
and B) antipsychotics for schizophrenia. Dark grey nodes correspond to treatments compared in 
RCTs only; light grey nodes are examined in RCTs and NRSs. The size of each node is proportional 
to the number of studies that examine the corresponding treatment. The thickness of edges is 
proportional to the number of patients included in the studies that made the corresponding 
comparison. Codes for percutaneous interventions (Panel A): A=balloon angioplasty, Β= bare 
metal stents, C=drug-coated balloons, D=everolimus-eluting stents, E=paclitaxel-eluting stents, 
F=rotablation, G= sirolimus-eluting stents, H=vascular brachytherapy 
 
Figure 2: Relative treatment effects (log OR and their 95% Confidence Intervals) for target–lesion 
revascularization with percutaneous interventions for coronary in-stent restenosis, estimated from 
the various sources of evidence. The results from NMA using only RCTs and from NMA using both 
RCTs and NRS (naïve NMA) are also presented. Only treatment comparisons informed by both 
randomized and non-randomized evidence are presented. Codes of interventions as per Figure 1. 
 
Figure 3: Relative treatment effects (Standardized Mean Differences SMD and their 95% Credible 
Intervals) for improvement in symptoms scale with antipsychotics in patients with schizophrenia 
estimated from the various sources of evidence.  The results from NMA using only RCTs and from 
NMA using both RCTs and NRS (naïve NMA) are also presented. Only treatment comparisons 
informed by both randomized and non-randomized evidence are presented. 
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Figure 4: Relative treatment effects (log OR and their 95% Confidence Intervals) for target–lesion 
revascularization with percutaneous interventions for coronary in-stent restenosis estimated using 
approach A.  Evidence from the NRSs is given increasing weight with the parameter w. Only 
treatment comparisons informed by both randomized and non-randomized evidence are presented. 
Codes of interventions as per Figure 1 
 
Figure 5: Relative treatment effects (Standardized Mean Differences SMD and their 95% Credible 
Intervals) for improvement in symptoms scale with antipsychotics in patients with schizophrenia. A 
large NRS is contributing data to form an informative prior (approach B). Evidence from the NRS 
is given increasing weight with the parameter w.  Only treatment comparisons informed by both 
randomized and non-randomized evidence are presented.   
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Networks of evidence for A) percutaneous interventions for coronary in-stent restenosis, and B) 
antipsychotics for schizophrenia. Dark grey nodes correspond to treatments compared in RCTs only; light 
grey nodes are examined in RCTs and NRSs. The size of each node is proportional to the number of studies 
that examine the corresponding treatment. The thickness of edges is proportional to the number of patients 
included in the studies that made the corresponding comparison. Codes for percutaneous interventions 
(Panel A): A=balloon angioplasty, Β= bare metal stents, C=drug-coated balloons, D=everolimus-eluting 
stents, E=paclitaxel-eluting stents, F=rotablation, G= sirolimus-eluting stents, H=vascular brachytherapy  
Figure 1  
124x75mm (300 x 300 DPI)  
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Relative treatment effects (log OR and their 95% Confidence Intervals) for target–lesion revascularization 
with percutaneous interventions for coronary in-stent restenosis, estimated from the various sources of 
evidence. The results from NMA using only RCTs and from NMA using both RCTs and NRS (naïve NMA) are 
also presented. Only treatment comparisons informed by both randomized and non-randomized evidence 
are presented. Codes of interventions as per Figure 1.  
Figure 2  
130x55mm (300 x 300 DPI)  
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Relative treatment effects (Standardized Mean Differences SMD and their 95% Credible Intervals) for 
improvement in symptoms scale with antipsychotics in patients with schizophrenia estimated from the 
various sources of evidence.  The results from NMA using only RCTs and from NMA using both RCTs and NRS 
(naïve NMA) are also presented. Only treatment comparisons informed by both randomized and non-
randomized evidence are presented.  
Figure 3  
133x52mm (300 x 300 DPI)  
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Relative treatment effects (log OR and their 95% Confidence Intervals) for target–lesion revascularization 
with percutaneous interventions for coronary in-stent restenosis estimated using approach A.  Evidence from 
the NRSs is given increasing weight with the parameter w. Only treatment comparisons informed by both 
randomized and non-randomized evidence are presented. Codes of interventions as per Figure 1  
Figure 4  
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Relative treatment effects (Standardized Mean Differences SMD and their 95% Credible Intervals) for 
improvement in symptoms scale with antipsychotics in patients with schizophrenia. A large NRS is 
contributing data to form an informative prior (approach B). Evidence from the NRS is given increasing 
weight with the parameter w.  Only treatment comparisons informed by both randomized and non-
randomized evidence are presented.    
Figure 5  
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Supplementary material for “Combining 
randomized and non-randomized evidence in 
network meta-analysis” 
Orestis Efthimiou
1
, Dimitris Mavridis
1,2
, Thomas P. A. Debray
3,4
, M. Samara
5
, S. 
Leucht
5
, M. Belger
6
, George C.M. Siontis
7
 and Georgia Salanti
1,8,9
 on behalf of 
GetReal Work Package 4 
1 Network meta-regression model 
Cooper et al. [1] and Salanti et al. [2] presented a general network meta-regression 
framework for including study-level covariates in a NMA of aggregated data. 
Equation (1) of the main paper is now updated as follows: 
 
~( , 
 ) ~ −  + ̅	 ,  (1) 
with ̅ being a study-level covariate and   the corresponding coefficient for the 
treatment comparison XvsY. Several alternative modeling choices can be made 
regarding the  coefficients. The simplest one is to pick a reference treatment for the 
regression, e.g. placebo, and to set the coefficients of all treatments versus this 
reference to be equal. This translates into assuming  =  for all treatments X≠P, 
with P being the reference treatment for the regression. From the consistency 
equations it then follows that all other  parameters are equal to zero. By using this 
formulation we assume that only relative treatment effects vs. P are influenced by 
covariate ; consequently, the choice of P becomes important. Note that P may or may 
not be the same as the treatment set to be the reference when picking the basic 
parameters of the model (this treatment can be arbitrarily chosen). Details about 
                                                
1
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alternative modeling choices can be in the original publications [1, 2] and also in our 
recent review [3]. 
An issue that may come up when using network meta-regression in practice is the 
issue of missing covariate data: in our case study, for example, the mean age and the 
mean duration of illness of participants are deemed to be important study-level effect 
modifiers. There are studies reporting mean age and duration, only age, only duration 
or none of these two covariates. Analyzing only the complete cases (studies reporting 
both covariates) would exclude from the analysis a significant number of studies. We 
can include in the network meta-regression model studies with missing covariates 
after using multiple imputations for the missing values. A simple way to 
stochastically impute values in a Bayesian setting is to draw values from a distribution 
centered on the mean of the available data. For example we can stochastically impute 
a missing value for the mean participant age in study 		by assuming      ~(̂"#$      , 
̂"#$       ), where ̂"#$       and 
̂"#$       are the mean value and standard deviation 
of the mean age in studies that report it.  
 This imputation method overlooks the fact that some covariates may be dependent 
on others. In our case study, for example, mean participant age and duration of illness 
are highly correlated. To also take this into account we can assume a model that draws 
the missing covariate values from a multivariate normal distribution centered on the 
mean of the available cases. More specifically we can assume that the mean age 
(     ) and mean duration of illness (%&     ) follow from: 
'     	%&      (~)*̂"#$      ̂+,-      . , ' 
̂"#$      
 /"#$0+,-
̂"#$      
̂+,-      /"#$0+,-
̂"#$      
̂+,-      
̂+,-       (1 
The full network meta-regression model for a 2-arm study  is the following: ~( , 
) ~ −  +      	"#$ + %&      	+,- ,  
where 2"#$ = "#$ and 2+,- = +,-		∀	4 ≠ 5, while 22"#$ = 22+,- = 0		∀	4. 
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2 Issues with Approach B (using non-randomized evidence as prior 
information) 
In this approach we perform an NMA in the RCTs, with the model being as in 
Equation (1) of the main paper, but we now assume informative prior distributions for 
the basic parameters. These follow from the analysis of the non-randomized data, 
after possibly shifting the mean and/or inflating the variance, e.g. ~(̂789 +:, ;<789/>).  
If the non-randomized evidence forms a network of evidence, however, 
formulating prior distributions for the basic parameters of the NMA of RCTs may 
become a non-trivial matter. To clarify this issue let us consider the example depicted 
in Figure 1 below. This shows a network of randomized studies comparing treatments 
A-H. Seven basic parameters need to be included in the model (equal to the number of 
treatments minus one). Let us assume that there are some NRSs informing AB, some 
NRSs informing CD, and a network of NRSs informing the comparisons between 
treatments E, F, G and H (thick black lines in Figure 1). In the first step we analyze all 
non-randomized evidence, i.e. we perform meta-analyses of the AB and CD studies 
and a NMA of the studies comparing E, F, G and H. For considerations regarding how 
to model heterogeneity in such cases we refer the reader to the main paper.   
In the second step, we use the estimates obtained from the first step to formulate 
predictive prior distributions for the basic parameters of the NMA of the RCTs. If for 
example treatment A is chosen to be the reference, then for the basic parameters AC 
and AD the prior distribution should be a bivariate normal distribution with 
parameters carefully chosen so that they carry no information about AC and AD, but 
so that they do carry information about CD: 
 ?@AB~ '*  + ̂@A789. , * ;C DEFDEF ; .	( (2) 
where  is an arbitrary constant, e.g. it can be set equal to zero with no loss of 
generality. Given that @A = A − @, the configuration above ensures that the 
prior information about CD is centered on ̂@A789, exactly as it should. Constants ;C and ; should be large enough (e.g. ;C = ; = 1000) to ensure that the marginal 
distributions for @ and A remain uninformative (since the non-randomized 
evidence provides no information about AC or AD). Given that ;&(@A) =;&(A) + ;&(@) − 2DEF(A , @), it follows that the DEF parameter of 
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Equation (2) should be set equal to DEF = (;C + ; − ;<@A789)/2. This choice ensures 
that Equation (2) incorporates the correct amount of uncertainty for the CD 
comparison. Similarly, for the case of the basic parameters AE, AF, AG and AH a 
multivariate normal distribution with 4 components needs to be used, with the 
variance-covariance matrix carefully structured so as to include the information 
conveyed in the non-randomized studies regarding  EF, EG, EH, FG, FH and GH. 
One can greatly simplify this complicated process by cleverly choosing the basic 
parameters. This is depicted using red lines in Figure 1. The non-randomized evidence 
can provide information about five basic parameters, so we choose AB, CD, EF, EG, 
EH. For AB and CD we need univariate normal distributions, i.e. (̂I789, ;<I789) and  (̂@A789, ;<@A789)  respectively. EF, EG and EH will be correlated so that multivariate 
normal distributions need to be used, as estimated from the non-randomized data, 
without any further complications. Two more basic parameters are needed, e.g. we 
can choose BC and DE, to which vague prior distributions need to be assigned.  
 
Figure 1: A network of eight treatments (A-H) including both randomized and non-
randomized studies. Thin black lines correspond to treatment comparisons for which 
only randomized evidence is available. Thick black lines correspond to comparisons 
for which non-randomized evidence is also available. Dashed red lines correspond to 
a possible choice of the seven basic parameters needed for the NMA model that uses 
non-randomized evidence as prior information. The basic parameters form a 
‘spanning tree’: they pass through all treatments and do not form any loops. Other 
choices of basic parameters are valid as well, e.g. AH could replace DE.  
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3 Relation between the mixture parameter and the variance inflation factor 
In Section 3.3 of the main paper we discuss three approaches for using non-
randomized evidence as prior information. Here we discuss how the mixture 
parameter of the third approach relates to the variance inflation factor >, for the 
special case of normal distributions.  
Let us focus to the case of a mixture prior for a single parameter. Assume that the 
informative part of the mixture prior (based on the non-randomized evidence) is (789, ;789), and let us also assume that the uninformative part is (0, ;J). The 
mixture prior is a linear combination of these two normal distributions, where 
parameter K controls the mixing. For fixed K this mixture prior is also a normal 
distribution, with variance equal to K;789 + (1 − K);J.  
If instead of a mixture we use a variance inflation factor (w), the variance of the 
prior distribution is ;789/>. By setting K;789 + (1 − K);J = ;789/>  we can 
calculate how the mixture parameter relates to w, i.e. what values of > and K lead to 
the same prior distribution. By solving for > we get > = 789(K;789 +(1 − K);J)0C. 
 
 
4 Approach C (three-level hierarchical models) 
Here we discuss the three-level hierarchical models presented in the main paper. 
For all three models we assume that at the first level the study  of the LMN design, 
compares X vs. Y and it is analyzed separately to provide an estimate of the relative 
effect O, with a standard error 
O. 
4.1 Model C.1 
For model C.1 at the second level a NMA is performed for each design, i.e. we 
assume   
 
O~(O , 
O ) O~(PO − PO, O) (3) 
where PO, PO,… are the basic parameters and O is the heterogeneity variance of 
the LMN design. The model can be extended to include multi-arm studies using standard 
NMA methodology. At the third level the basic parameters are assumed to be 
exchangeable across designs, i.e.  PO~(:, +$Q )	 
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PO~(:, +$Q )	 … 
All other relative treatment effects can be calculated by combining the estimates on 
the various P, e.g.  =  − .  
Note that for the NMA of each design we use as basic parameters a subset of the 
basic parameters synthesized at the third level. e.g. a design may provide information 
on basic parameters AB and AC, another design information on AB and AD etc.. This 
model will not be applicable in some scenarios. Let us consider the example depicted 
in Figure 2, where there are four treatments in total (A, B, C and D) and there are 
studies pertaining to three different designs. For the NMA of the first design one 
could use as basic parameters any two of the following three: AB, AC or BC. 
Similarly, for the second design any two of AB, AD and BD, while for the third 
design any two comparisons out of BC, BD and CD. It is evident that one cannot find 
a set of three basic parameters (number of total treatments minus one) so that every 
design could be meta-analyzed using a subset of this set.  
 
Figure 2:  A scenario for which model C.1 could not be used. 
 
 
4.2 Model C.2 
For model C.2 at the second level a simple, pairwise meta-analysis is performed 
for each comparison in each design, sharing however the same heterogeneity 
variance, i.e. we assume   O~(O , 
O ) O~(PO , O) 
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This is in essence the same model as in Equation (3), after excluding the 
consistency equations; this has been termed as the unrelated mean effects (UME) 
model [4]. If comparison-specific heterogeneities are assumed, this equation describes 
a series of unrelated pairwise meta-analyses. 
At the third level we synthesize all design-specific estimates of the second level 
into an NMA, allowing for design-level heterogeneity, i.e. we assume that: PO~(: −  , +$Q ) 
This model can handle scenarios like the one presented in Figure 2. In this example 
at the third level we would perform a NMA on the estimates obtained at the second 
level: PCI , PC@, PCI@ (from the 1st design), PI , PA, PIA (from the 2nd design) 
and PSI@ , PSIA, PS@A (from the 3rd design). These nine estimates would be analyzed at 
the third level as if they were obtained from a single study each. 
When multi-arm studies are present model C.2, becomes problematic. 
4.3 Model C.3 
For model C.3 at the second level a NMA is performed per design, imposing the 
consistency equations, exactly as in Equation (3). The output from each NMA is a 
vector of the estimated treatment effects, with a corresponding variance-covariance 
matrix. These estimates are used for the NMA at the third level, treated as if they 
belonged to multi-arm studies. For the example of Figure 2 at the second level we 
would estimate TU = (PC:I , PC:@)′ from design 1, TW = (P:I , PIA)′ from design 2 
and TX = (PSIA , PS@A)′ from design 3, along with YU, YW and YX, the three variance-
covariance matrices. Note that the choice of basic parameters in the NMA of each 
design is arbitrary, different choices will not change results. At the third level a NMA 
is again performed using these three estimates as if they belonged to a single multi-
arm trial each. For the running example we would assume that  
Z
[\
PC:IPC:@P:IPIAPSIAPS@A]
_^~
Z
[[[
\
Z
[[
\`C:I`C:@`:I`IA`SIA`S@A]
^^
_ ,aL(YUYW, YX)	
]
^^^
_
 
and  
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Z
[[
\`C:I`C:@`:I`IA`SIA`S@A]
^^
_~
Z
[[
\
Z
[\
:I:@:I:A − I:A − I:A − @]
_^ , aL(b, b, b)	
]
^^
_
 
where b = ' +$Q +$Q /2+$Q /2 +$Q ( is the design-level heterogeneity variance-covariance 
matrix. Note that the consistency equations are used at both the second and the third 
level.  
In all three models estimates from the NRSs can be adjusted either at the study 
level (by shifting the mean and/or inflating the variance) or at the design level, i.e. by 
adjusting the output of the design-level estimates separately for each design.  In 
Figure 3 we provide a schematic representation of the three alternative three-level 
hierarchical models presented in this paper.  
Page 39 of 58 Statistics in Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9 
 
Figure 3: Schematic representation of the three-level hierarchical models. 
Abbreviations: MA=meta-analysis, NMA=network meta-analysis 
Model C.1: an NMA per design at the 2
nd
 level, an MA per basic parameter at the 3
rd
 
level 
Model C.2: a MA per design at the 2
nd
 level, an overall NMA at the 3
rd
 level 
Model C.3: an NMA per design at the 2
nd
 level, an overall NMA at the 3
rd
 level.   
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5 Percutaneous interventions for the treatment of coronary in-stent restenosis 
example  
In this section we present some results from the analysis of the coronary in-stent 
restenosis network. The NRSs that we included in this analysis are given in the 
reference list of this appendix [5–10]. 
In order to assess the inconsistency we applied the loop-specific and the node-
splitting approaches. In Table 1 we present the results of the loop-specific approach 
for identifying inconsistency, for the case of the NMA with RCTs only. In Table 2 we 
give results for the naïve NMA. The analysis were performed using the ifplot 
command in Stata. The inconsistency factors (IF) presented in these tables correspond 
to the difference between direct and indirect evidence in each loop. 
Table 1: Inconsistency factors – NMA with RCTs only 
  +-------------------------------------------------------------------------------+ 
  |    Loop |    IF |  seIF | z_value | p_value |       CI_95 | Loop_Heterog_tau2 | 
  |---------+-------+-------+---------+---------+-------------+-------------------| 
  | A-C-D-G | 2.312 | 1.508 |   1.533 |   0.125 | (0.00,5.27) |             0.189 | 
  | C-D-E-G | 1.537 | 1.679 |   0.915 |   0.360 | (0.00,4.83) |             0.369 | 
  |   A-C-E | 0.939 | 0.739 |   1.271 |   0.204 | (0.00,2.39) |             0.282 | 
  |   A-E-G | 0.464 | 0.729 |   0.637 |   0.524 | (0.00,1.89) |             0.218 | 
  |   E-G-H | 0.337 | 1.038 |   0.324 |   0.746 | (0.00,2.37) |             0.439 | 
  |   A-E-H | 0.277 | 0.445 |   0.623 |   0.533 | (0.00,1.15) |             0.019 | 
  |   A-B-F | 0.138 | 0.992 |   0.139 |   0.889 | (0.00,2.08) |             0.281 | 
  |   A-G-H | 0.092 | 0.416 |   0.220 |   0.826 | (0.00,0.91) |             0.022 | 
  +-------------------------------------------------------------------------------+ 
 
Table 2: Inconsistency factors – naïve NMA 
  +-----------------------------------------------------------------------------+ 
  |  Loop |    IF |  seIF | z_value | p_value |       CI_95 | Loop_Heterog_tau2 | 
  |-------+-------+-------+---------+---------+-------------+-------------------| 
  | A-C-D | 1.844 | 1.479 |   1.247 |   0.213 | (0.00,4.74) |             0.811 | 
  | A-D-E | 1.481 | 1.026 |   1.443 |   0.149 | (0.00,3.49) |             0.232 | 
  | A-D-G | 1.253 | 0.664 |   1.885 |   0.059 | (0.00,2.55) |             0.000 | 
  | A-C-E | 0.939 | 0.739 |   1.271 |   0.204 | (0.00,2.39) |             0.282 | 
  | A-E-G | 0.498 | 0.559 |   0.891 |   0.373 | (0.00,1.59) |             0.143 | 
  | C-D-E | 0.413 | 1.272 |   0.325 |   0.745 | (0.00,2.91) |             0.732 | 
  | A-G-H | 0.307 | 0.515 |   0.597 |   0.550 | (0.00,1.32) |             0.101 | 
  | A-E-H | 0.277 | 0.445 |   0.623 |   0.533 | (0.00,1.15) |             0.019 | 
  | D-E-G | 0.256 | 0.769 |   0.333 |   0.739 | (0.00,1.76) |             0.238 | 
  | E-G-H | 0.156 | 0.770 |   0.203 |   0.839 | (0.00,1.67) |             0.212 | 
  | A-B-F | 0.138 | 0.992 |   0.139 |   0.889 | (0.00,2.08) |             0.281 | 
  +-----------------------------------------------------------------------------+ 
 
In Table 3 we give results from the node-splitting approach for assessing 
inconsistency, before and after the inclusion of NRSs in the network. Analyses were 
performed using the network sidesplit command in Stata.  
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Table 3: Estimates from the node-splitting approach for assessing inconsistency. 
  
difference between direct and indirect evidence 
(standard error) 
comparison split only RCTs RCTs and NRSs 
AvsB 0.07 (0.85) 0.11 (0.94) 
AvsC 0.64 (0.58) 0.71 (0.54) 
AvsE 0.35 (0.48) 0.11 (0.52) 
AvsF 0.07 (0.85) 0.11 (0.94) 
AvsG 0.36 (0.51) 0.49 (0.48) 
AvsH 0.04 (0.48) 0.29 (0.50) 
BvsF 0.07 (0.85) 0.11 (0.94) 
CvsD 2.11 (1.43) 0.51 (0.64) 
CvsE 0.83 (0.53) 0.72 (0.53) 
DvsG 2.11 (1.43) 0.25 (0.64) 
EvsG 0.60 (0.51) 0.34 (0.51) 
EvsH 0.18 (0.58) 0.19 (0.64) 
GvsH 0.10 (0.53) 0.20 (0.59) 
AvsD - 1.68 (0.68) 
 
In Table 4 we give the estimates for the heterogeneity variance (τ
2
) for the analyses 
discussed in Section 5.2 of the main paper.  
Table 4: Estimates for the heterogeneity variance (assumed common in the network) 
Analysis (approach A) Heterogeneity (τ
2
) 
RCTs only 0.13 
w = 0.2 0.12 
w = 0.5 0.14 
w = 0.8 0.18 
Naïve analysis (w = 1) 0.20 
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6 Using model C for the antipsychotics example 
As we discussed in Section 3.3 of the main paper, approach C requires the 
availability of multiple study designs. We were, however, unable to identify any 
suitable example to use for illustrating the method. Thus, in order to exemplify 
approach C we used the antipsychotics example after splitting the available RCTs in 
groups and treating each of these groups as if it pertained to a different design. We do 
the splitting according to the risk of bias (RoB) assessment that was performed in the 
original publication [11]. The authors had assessed each RCT as being of “high RoB”, 
“low RoB” or “unclear”, for each one of the following five bias domains: 
randomization, allocation, blinding, missing outcomes and other biases. Using this 
assessment, we created three groups. The first group (‘high RoB RCTs’) incorporated 
all studies judged to be at a high RoB for at least one of the five bias domains; this 
group included 97 RCTs. The second group (‘low RoB RCTs’) included studies 
judged to be at a low RoB for at least four of the five bias domains; only 18 studies 
were included in this group. The rest of the studies were grouped into a ‘unclear RoB’ 
group of RCTs; there were 52 such studies. We then treated the groups as being 
different designs, and we assumed the single NRS to be of a different design. We used 
model C1 presented in Section 3.3 to synthesize the data. 
 
7 Results for the antipsychotics example 
7.1 Results from the naïve analysis 
In Table 5 we give the estimates from all model parameters of the naïve NMA. The 
regression coefficients correspond to the comparison of all active drugs vs. placebo.  
In Tables 2 and 3 we give the results from the inconsistency factors (i.e. the difference 
between direct and indirect evidence in each loop) for all loops in the network, before 
and after the inclusion of the observational study. In Table 8 we present results from 
the node-splitting approach for assessing inconsistency.  
 
Table 5: Naïve analysis - estimates of the model parameters 
Parameter Median estimate (95% Cr.I.)   
(heterogeneity SD) 
0.085 
(0.052, 0.120) "#$ 
(regression coefficient for mean age) 
0.10 
(-0.10, 0.28) +,- 
(regression coefficient for mean duration of illness) 
0.00 
(-0.22, 0.22) 
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/"#$0+,- 
(correlation coefficient between mean age and mean 
duration of illness) 
0.89 
(0.85, 0.92) 
 
Table 6: Inconsistency factors – NMA with RCT only 
+--------------------------------------------------------------------------------+ 
|     Loop |    IF |  seIF | z_value | p_value |   CI_95     | Loop_Heterog_tau2 | 
|----------+-------+-------+---------+---------+-------------+-------------------| 
|   2-7-10 | 1.235 | 0.639 |   1.933 |   0.053 | (0.00,2.49) |             0.081 | 
|   3-4-15 | 1.119 | 0.613 |   1.825 |   0.068 | (0.00,2.32) |             0.045 | 
|   3-7-10 | 0.810 | 0.271 |   2.986 |   0.003 | (0.28,1.34) |             0.000 | 
|   3-7-15 | 0.772 | 0.596 |   1.296 |   0.195 | (0.00,1.94) |             0.059 | 
|   1-3-15 | 0.734 | 0.571 |   1.285 |   0.199 | (0.00,1.85) |             0.005 | 
|  3-10-15 | 0.732 | 0.698 |   1.049 |   0.294 | (0.00,2.10) |             0.070 | 
|  7-10-15 | 0.707 | 0.505 |   1.401 |   0.161 | (0.00,1.70) |             0.092 | 
|   2-3-15 | 0.677 | 0.553 |   1.224 |   0.221 | (0.00,1.76) |             0.018 | 
|   1-3-12 | 0.567 | 0.258 |   2.203 |   0.028 | (0.06,1.07) |             0.013 | 
|    5-8-9 | 0.529 | 0.352 |   1.500 |   0.134 | (0.00,1.22) |             0.000 | 
|    2-5-8 | 0.504 | 0.327 |   1.538 |   0.124 | (0.00,1.15) |             0.000 | 
|   1-2-14 | 0.451 | 0.323 |   1.397 |   0.163 | (0.00,1.08) |             0.036 | 
|    2-5-7 | 0.443 | 0.438 |   1.010 |   0.312 | (0.00,1.30) |             0.000 | 
|   2-4-15 | 0.415 | 0.273 |   1.520 |   0.128 | (0.00,0.95) |             0.015 | 
|    3-5-8 | 0.413 | 0.369 |   1.119 |   0.263 | (0.00,1.14) |             0.023 | 
|    2-3-7 | 0.408 | 0.438 |   0.931 |   0.352 | (0.00,1.27) |             0.009 | 
|   1-3-14 | 0.378 | 0.201 |   1.881 |   0.060 | (0.00,0.77) |             0.004 | 
|   1-4-15 | 0.368 | 0.299 |   1.229 |   0.219 | (0.00,0.95) |             0.000 | 
|    1-5-8 | 0.362 | 0.336 |   1.078 |   0.281 | (0.00,1.02) |             0.000 | 
|   2-3-12 | 0.361 | 0.197 |   1.835 |   0.067 | (0.00,0.75) |             0.013 | 
|   3-4-12 | 0.341 | 0.160 |   2.137 |   0.033 | (0.03,0.65) |             0.019 | 
|   1-4-14 | 0.334 | 0.191 |   1.749 |   0.080 | (0.00,0.71) |             0.000 | 
| 4-5-7-15 | 0.320 | 0.307 |   1.044 |   0.297 | (0.00,0.92) |             0.007 | 
|   1-2-12 | 0.306 | 0.436 |   0.701 |   0.483 | (0.00,1.16) |             0.048 | 
|   2-7-15 | 0.286 | 0.574 |   0.498 |   0.618 | (0.00,1.41) |             0.095 | 
|   2-4-13 | 0.286 | 0.188 |   1.519 |   0.129 | (0.00,0.65) |             0.000 | 
|  2-10-15 | 0.251 | 0.407 |   0.617 |   0.537 | (0.00,1.05) |             0.102 | 
|    4-5-8 | 0.249 | 0.326 |   0.763 |   0.446 | (0.00,0.89) |             0.000 | 
|    4-8-9 | 0.246 | 0.148 |   1.661 |   0.097 | (0.00,0.54) |             0.000 | 
|    1-2-9 | 0.217 | 0.250 |   0.870 |   0.384 | (0.00,0.71) |             0.036 | 
|   1-4-12 | 0.199 | 0.202 |   0.988 |   0.323 | (0.00,0.59) |             0.000 | 
|   1-9-11 | 0.196 | 0.154 |   1.276 |   0.202 | (0.00,0.50) |             0.001 | 
|    1-2-5 | 0.195 | 0.177 |   1.105 |   0.269 | (0.00,0.54) |             0.022 | 
|    2-4-5 | 0.176 | 0.102 |   1.719 |   0.086 | (0.00,0.38) |             0.000 | 
|   2-3-11 | 0.173 | 0.087 |   1.983 |   0.047 | (0.00,0.34) |             0.000 | 
|    1-8-9 | 0.171 | 0.179 |   0.952 |   0.341 | (0.00,0.52) |             0.000 | 
|   3-5-13 | 0.157 | 0.261 |   0.602 |   0.547 | (0.00,0.67) |             0.037 | 
|   3-9-11 | 0.156 | 0.148 |   1.055 |   0.291 | (0.00,0.45) |             0.000 | 
|    2-4-9 | 0.155 | 0.101 |   1.531 |   0.126 | (0.00,0.35) |             0.000 | 
|    2-4-6 | 0.148 | 0.154 |   0.961 |   0.336 | (0.00,0.45) |             0.009 | 
|    1-3-5 | 0.117 | 0.127 |   0.918 |   0.358 | (0.00,0.37) |             0.017 | 
|    1-3-9 | 0.117 | 0.122 |   0.955 |   0.339 | (0.00,0.36) |             0.003 | 
|   3-4-13 | 0.109 | 0.295 |   0.371 |   0.710 | (0.00,0.69) |             0.054 | 
|   2-3-10 | 0.106 | 0.218 |   0.484 |   0.628 | (0.00,0.53) |             0.012 | 
|    3-8-9 | 0.103 | 0.158 |   0.649 |   0.516 | (0.00,0.41) |             0.000 | 
|    1-2-3 | 0.098 | 0.113 |   0.867 |   0.386 | (0.00,0.32) |             0.020 | 
|    3-4-8 | 0.097 | 0.147 |   0.658 |   0.511 | (0.00,0.39) |             0.020 | 
|   4-5-13 | 0.093 | 0.171 |   0.546 |   0.585 | (0.00,0.43) |             0.000 | 
|    1-4-8 | 0.092 | 0.126 |   0.728 |   0.467 | (0.00,0.34) |             0.000 | 
|   2-3-13 | 0.084 | 0.234 |   0.360 |   0.719 | (0.00,0.54) |             0.023 | 
|    1-2-6 | 0.084 | 0.194 |   0.431 |   0.666 | (0.00,0.46) |             0.025 | 
|    2-4-8 | 0.076 | 0.081 |   0.933 |   0.351 | (0.00,0.24) |             0.000 | 
|    2-3-8 | 0.075 | 0.089 |   0.838 |   0.402 | (0.00,0.25) |             0.000 | 
|    1-2-4 | 0.070 | 0.108 |   0.651 |   0.515 | (0.00,0.28) |             0.009 | 
|    1-2-8 | 0.067 | 0.223 |   0.300 |   0.764 | (0.00,0.50) |             0.028 | 
|   2-9-11 | 0.067 | 0.139 |   0.481 |   0.631 | (0.00,0.34) |             0.000 | 
|    1-3-8 | 0.062 | 0.127 |   0.488 |   0.626 | (0.00,0.31) |             0.000 | 
|    1-3-4 | 0.060 | 0.107 |   0.564 |   0.573 | (0.00,0.27) |             0.015 | 
|    3-4-5 | 0.060 | 0.162 |   0.368 |   0.713 | (0.00,0.38) |             0.039 | 
|    3-5-7 | 0.056 | 0.307 |   0.182 |   0.855 | (0.00,0.66) |             0.048 | 
|    4-5-9 | 0.052 | 0.148 |   0.353 |   0.724 | (0.00,0.34) |             0.000 | 
|    2-3-4 | 0.051 | 0.106 |   0.485 |   0.628 | (0.00,0.26) |             0.018 | 
|   2-4-14 | 0.049 | 0.130 |   0.377 |   0.706 | (0.00,0.30) |             0.000 | 
|    1-5-9 | 0.048 | 0.143 |   0.333 |   0.739 | (0.00,0.33) |             0.001 | 
|    3-4-9 | 0.045 | 0.163 |   0.274 |   0.784 | (0.00,0.37) |             0.025 | 
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|   2-4-12 | 0.044 | 0.134 |   0.328 |   0.743 | (0.00,0.31) |             0.000 | 
| 1-5-7-15 | 0.041 | 0.339 |   0.120 |   0.904 | (0.00,0.71) |             0.011 | 
|   1-3-11 | 0.040 | 0.117 |   0.340 |   0.734 | (0.00,0.27) |             0.002 | 
|   1-2-11 | 0.037 | 0.198 |   0.187 |   0.851 | (0.00,0.42) |             0.022 | 
|   1-2-15 | 0.035 | 0.353 |   0.099 |   0.921 | (0.00,0.73) |             0.053 | 
|    2-3-9 | 0.026 | 0.123 |   0.209 |   0.834 | (0.00,0.27) |             0.003 | 
|    1-4-5 | 0.022 | 0.110 |   0.202 |   0.840 | (0.00,0.24) |             0.000 | 
|    1-4-9 | 0.017 | 0.110 |   0.153 |   0.878 | (0.00,0.23) |             0.000 | 
|   2-5-13 | 0.017 | 0.199 |   0.084 |   0.933 | (0.00,0.41) |             0.000 | 
|   2-3-14 | 0.015 | 0.138 |   0.106 |   0.915 | (0.00,0.29) |             0.006 | 
|    2-8-9 | 0.014 | 0.161 |   0.090 |   0.928 | (0.00,0.33) |             0.000 | 
|    3-5-9 | 0.012 | 0.247 |   0.049 |   0.961 | (0.00,0.50) |             0.031 | 
|    2-5-9 | 0.010 | 0.140 |   0.074 |   0.941 | (0.00,0.29) |             0.000 | 
|    1-4-6 | 0.009 | 0.135 |   0.070 |   0.945 | (0.00,0.27) |             0.002 | 
|   3-4-16 | 0.007 | 0.164 |   0.045 |   0.964 | (0.00,0.33) |             0.031 | 
|    2-3-5 | 0.007 | 0.142 |   0.048 |   0.962 | (0.00,0.28) |             0.018 | 
|   3-4-14 | 0.004 | 0.281 |   0.014 |   0.989 | (0.00,0.56) |             0.039 | 
+--------------------------------------------------------------------------------+ 
 
Table 7: Inconsistency factors – NMA with RCT and observational study 
+-------------------------------------------------------------------------------+ 
|    Loop |    IF |  seIF | z_value | p_value |       CI_95 | Loop_Heterog_tau2 | 
|---------+-------+-------+---------+---------+-------------+-------------------| 
|  2-7-10 | 1.228 | 0.639 |   1.922 |   0.055 | (0.00,2.48) |             0.081 | 
|  3-4-15 | 1.013 | 0.573 |   1.769 |   0.077 | (0.00,2.14) |             0.041 | 
|  3-5-15 | 0.893 | 0.600 |   1.488 |   0.137 | (0.00,2.07) |             0.049 | 
|  1-3-15 | 0.820 | 0.522 |   1.572 |   0.116 | (0.00,1.84) |             0.004 | 
|  3-7-10 | 0.799 | 0.271 |   2.945 |   0.003 | (0.27,1.33) |             0.000 | 
|  3-7-15 | 0.761 | 0.591 |   1.287 |   0.198 | (0.00,1.92) |             0.054 | 
| 7-10-15 | 0.708 | 0.502 |   1.409 |   0.159 | (0.00,1.69) |             0.091 | 
| 3-10-15 | 0.705 | 0.698 |   1.011 |   0.312 | (0.00,2.07) |             0.070 | 
|  2-3-15 | 0.650 | 0.553 |   1.176 |   0.240 | (0.00,1.73) |             0.017 | 
|  1-3-12 | 0.568 | 0.257 |   2.204 |   0.027 | (0.06,1.07) |             0.013 | 
|   2-5-8 | 0.506 | 0.327 |   1.547 |   0.122 | (0.00,1.15) |             0.000 | 
|  1-2-14 | 0.453 | 0.327 |   1.385 |   0.166 | (0.00,1.09) |             0.037 | 
|   2-5-7 | 0.438 | 0.438 |   1.000 |   0.317 | (0.00,1.30) |             0.000 | 
|   3-5-8 | 0.415 | 0.368 |   1.127 |   0.260 | (0.00,1.14) |             0.023 | 
|   2-3-7 | 0.411 | 0.436 |   0.944 |   0.345 | (0.00,1.26) |             0.008 | 
|   1-5-8 | 0.389 | 0.333 |   1.170 |  0.242 | (0.00,1.04) |             0.000 | 
|  1-3-14 | 0.379 | 0.201 |   1.887 |   0.059 | (0.00,0.77) |             0.004 | 
|   4-5-8 | 0.359 | 0.322 |   1.118 |   0.264 | (0.00,0.99) |             0.000 | 
|  2-3-12 | 0.358 | 0.194 |   1.848 |   0.065 | (0.00,0.74) |             0.013 | 
|   2-5-6 | 0.342 | 0.121 |   2.831 |   0.005 | (0.11,0.58) |             0.000 | 
|  3-4-12 | 0.340 | 0.159 |   2.138 |   0.032 | (0.03,0.65) |             0.019 | 
|  1-2-12 | 0.307 | 0.442 |   0.696 |   0.486 | (0.00,1.17) |             0.049 | 
|  2-4-15 | 0.302 | 0.183 |   1.653 |   0.098 | (0.00,0.66) |             0.014 | 
|  2-4-13 | 0.285 | 0.188 |   1.517 |   0.129 | (0.00,0.65) |             0.000 | 
|  2-7-15 | 0.278 | 0.576 |   0.482 |   0.630 | (0.00,1.41) |             0.096 | 
|  1-4-14 | 0.271 | 0.186 |   1.460 |   0.144 | (0.00,0.63) |             0.000 | 
| 2-10-15 | 0.254 | 0.410 |   0.619 |   0.536 | (0.00,1.06) |             0.104 | 
|  4-6-15 | 0.251 | 0.406 |   0.619 |   0.536 | (0.00,1.05) |             0.068 | 
|   4-8-9 | 0.246 | 0.148 |   1.662 |   0.097 | (0.00,0.54) |             0.000 | 
|  2-5-15 | 0.241 | 0.289 |   0.831 |   0.406 | (0.00,0.81) |             0.033 | 
|   2-4-6 | 0.230 | 0.141 |   1.630 |   0.103 | (0.00,0.51) |             0.011 | 
|   1-2-9 | 0.218 | 0.253 |   0.862 |   0.389 | (0.00,0.71) |             0.037 | 
|  1-9-11 | 0.196 | 0.154 |   1.273 |   0.203 | (0.00,0.50) |             0.001 | 
|  4-5-13 | 0.178 | 0.178 |   1.005 |   0.315 | (0.00,0.53) |             0.002 | 
|   1-2-5 | 0.177 | 0.158 |   1.123 |   0.262 | (0.00,0.49) |             0.015 | 
|  2-3-11 | 0.172 | 0.087 |   1.966 |   0.049 | (0.00,0.34) |             0.000 | 
|   1-8-9 | 0.171 | 0.179 |   0.953 |   0.341 | (0.00,0.52) |             0.000 | 
|  3-5-13 | 0.157 | 0.261 |   0.604 |   0.546 | (0.00,0.67) |             0.037 | 
|   2-4-9 | 0.155 | 0.101 |   1.529 |   0.126 | (0.00,0.35) |             0.000 | 
|  3-9-11 | 0.155 | 0.148 |   1.048 |   0.295 | (0.00,0.44) |             0.000 | 
|  4-5-15 | 0.149 | 0.103 |   1.453 |   0.146 | (0.00,0.35) |             0.000 | 
|  1-4-12 | 0.136 | 0.197 |   0.690 |   0.490 | (0.00,0.52) |             0.000 | 
|   1-2-6 | 0.119 | 0.171 |   0.694 |   0.488 | (0.00,0.45) |             0.021 | 
|   1-3-9 | 0.118 | 0.122 |   0.962 |   0.336 | (0.00,0.36) |             0.003 | 
|  5-7-15 | 0.113 | 0.455 |   0.247 |   0.805 | (0.00,1.00) |             0.075 | 
|  3-4-13 | 0.109 | 0.294 |   0.370 |   0.712 | (0.00,0.68) |             0.054 | 
|  2-3-10 | 0.105 | 0.216 |   0.484 |   0.628 | (0.00,0.53) |             0.011 | 
|   1-4-5 | 0.104 | 0.085 |   1.223 |   0.221 | (0.00,0.27) |             0.000 | 
|   3-8-9 | 0.103 | 0.158 |   0.648 |   0.517 | (0.00,0.41) |             0.000 | 
|   1-3-5 | 0.102 | 0.114 |   0.900 |   0.368 | (0.00,0.33) |             0.012 | 
|   4-5-9 | 0.102 | 0.111 |   0.917 |   0.359 | (0.00,0.32) |             0.000 | 
|   3-4-8 | 0.098 | 0.147 |   0.666 |   0.506 | (0.00,0.39) |             0.020 | 
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|  1-6-15 | 0.097 | 0.123 |   0.795 |   0.427 | (0.00,0.34) |             0.000 | 
|  1-4-15 | 0.097 | 0.092 |   1.049 |   0.294 | (0.00,0.28) |             0.000 | 
|   1-2-3 | 0.096 | 0.113 |   0.855 |   0.393 | (0.00,0.32) |             0.020 | 
|   1-2-4 | 0.090 | 0.099 |   0.905 |   0.365 | (0.00,0.28) |             0.008 | 
|  2-3-13 | 0.085 | 0.232 |   0.367 |   0.713 | (0.00,0.54) |             0.023 | 
|   1-3-4 | 0.081 | 0.098 |   0.822 |   0.411 | (0.00,0.27) |             0.012 | 
|  2-6-15 | 0.077 | 0.264 |   0.294 |   0.769 | (0.00,0.59) |             0.029 | 
|   2-4-8 | 0.076 | 0.081 |   0.934 |   0.350 | (0.00,0.24) |             0.000 | 
|   2-3-8 | 0.074 | 0.089 |   0.830 |   0.407 | (0.00,0.25) |             0.000 | 
|   1-2-8 | 0.068 | 0.226 |   0.301 |   0.764 | (0.00,0.51) |             0.029 | 
|  2-9-11 | 0.067 | 0.139 |   0.480 |   0.631 | (0.00,0.34) |             0.000 | 
|   2-4-5 | 0.066 | 0.086 |   0.764 |   0.445 | (0.00,0.23) |             0.000 | 
|   1-3-8 | 0.062 | 0.127 |   0.492 |   0.623 | (0.00,0.31) |             0.000 | 
|   1-4-9 | 0.057 | 0.092 |   0.616 |   0.538 | (0.00,0.24) |             0.000 | 
|   2-3-4 | 0.051 | 0.105 |   0.487 |   0.626 | (0.00,0.26) |             0.018 | 
|  1-2-15 | 0.050 | 0.262 |   0.191 |   0.849 | (0.00,0.56) |             0.050 | 
|  2-4-14 | 0.049 | 0.130 |   0.376 |   0.707 | (0.00,0.30) |             0.000 | 
|   3-5-7 | 0.047 | 0.304 |   0.155 |   0.877 | (0.00,0.64) |             0.046 | 
|   3-4-9 | 0.044 | 0.163 |   0.273 |   0.785 | (0.00,0.36) |             0.025 | 
|  2-4-12 | 0.044 | 0.134 |   0.328 |   0.743 | (0.00,0.31) |             0.000 | 
|   1-5-9 | 0.043 | 0.121 |   0.354 |   0.723 | (0.00,0.28) |             0.000 | 
|  1-3-11 | 0.040 | 0.117 |   0.341 |   0.733 | (0.00,0.27) |             0.002 | 
|  1-2-11 | 0.036 | 0.201 |   0.178 |   0.859 | (0.00,0.43) |             0.023 | 
|   1-4-6 | 0.034 | 0.110 |   0.309 |   0.757 | (0.00,0.25) |             0.006 | 
|  1-5-15 | 0.033 | 0.097 |   0.340 |   0.734 | (0.00,0.22) |             0.000 | 
|   2-3-9 | 0.026 | 0.121 |   0.212 |   0.832 | (0.00,0.26) |             0.002 | 
|   3-4-5 | 0.025 | 0.144 |   0.174 |   0.861 | (0.00,0.31) |             0.032 | 
|   1-4-8 | 0.022 | 0.117 |   0.191 |   0.848 | (0.00,0.25) |             0.000 | 
|  2-5-13 | 0.016 | 0.199 |   0.082 |   0.935 | (0.00,0.41) |             0.000 | 
|   2-8-9 | 0.015 | 0.160 |   0.092 |   0.927 | (0.00,0.33) |             0.000 | 
|  2-3-14 | 0.013 | 0.136 |   0.096 |   0.923 | (0.00,0.28) |             0.005 | 
|   1-5-6 | 0.013 | 0.085 |   0.148 |   0.882 | (0.00,0.18) |             0.000 | 
|   3-5-9 | 0.012 | 0.246 |   0.050 |   0.960 | (0.00,0.50) |             0.031 | 
|   2-5-9 | 0.010 | 0.140 |   0.073 |   0.942 | (0.00,0.29) |             0.000 | 
|  3-4-16 | 0.009 | 0.164 |   0.053 |   0.958 | (0.00,0.33) |             0.031 | 
|   2-3-5 | 0.005 | 0.141 |   0.038 |   0.970 | (0.00,0.28) |             0.018 | 
|  3-4-14 | 0.003 | 0.280 |   0.011 |   0.992 | (0.00,0.55) |             0.039 | 
|   4-5-6 | 0.002 | 0.245 |   0.008 |   0.993 | (0.00,0.48) |             0.028 | 
+-------------------------------------------------------------------------------+ 
 
Table 8: Estimates from the node-splitting approach for assessing inconsistency. 
  
difference between direct and indirect evidence 
(standard error) 
comparison split only RCTs RCTs and observational 
1v4 0.03 (0.08) 0.05 (0.07) 
1v5 0.12 (0.09) 0.10 (0.08) 
1v6  0.07 (0.13) 0.08 (0.10) 
1v15 0.05 (0.25)  0.02 (0.12) 
4v5  0.09 (0.10) 0.02 (0.08) 
4v6 0.09 (0.12)  0.17 (0.10) 
4v15 0.37 (0.23)  0.25 (0.12) 
5v6 -  0.16 (0.13) 
5v15 - 0.08 (0.14) 
6v15 -  0.11 (0.15) 
 
7.2 Results: approach B 
The model estimates for the model parameters "#$ , +,- and /"#$0+,- are similar 
to the ones presented in Table 5 for all explored scenarios. The estimate for the 
heterogeneity standard deviation, , does not change across the different scenarios: 
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0.080 (0.042, 0.120). This should be expected since in model B the NRSs are used to 
formulate informative prior distributions, and do not have any effect on the estimation 
of  .  
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8 OpenBUGS code for the presented models  
Here we provide the codes used to implement the Bayesian models presented in the 
main paper (used in the schizophrenia example). Comments on the code are written in 
blue. The dataset includes 167 RCTs and one non-randomized study. The following 
data are required as input: 
ns: number of RCTs (in our example 167) 
nt: number of treatments in the network (in our example 16) 
agedur: a table with dimensions c
 × 2, with the mean patients’ age and mean 
duration of illness for each study. These two covariates are standardized (by 
subtracting the mean and dividing by the standard deviation) so as to improve 
convergence 
t: a table with dimensions c
 × 4, with information on the treatments being compared 
in each study. Each study is coded as a number between 1 and nt. A two-arm study 
has two entries in t and the rest are set equal to NA. A three-arm study has three 
entries, etc. In our example the maximum number of arms in an RCT is 4.  
na: a vector with the number of arms in each RCT (2 for two-armed studies, 3 for 
three-armed studies etc.) 
ref: the code of the reference treatment of the network. The choice of treatment to be 
the reference is arbitrary. 
regress.ref: the code of the treatment to be the reference in meta-regression. In our 
case we chose placebo. 
y: a table with the mean outcome for each study arm, with dimensions c
 × cf. When 
a treatment is not included in a study the corresponding entry is set to NA. 
sd: a table with the standard deviations for each study arm, with dimensions c
 × cf. 
When a treatment is not included in a study the corresponding entry is arbitrarily 
imputed with a non-negative number, e.g. set equal to zero. 
n: a table with the number of patients randomized in each study arm, with dimensions c
 × cf. When a treatment is not included in a study the corresponding entry is set to 
one. 
nt.NRS: the number of treatments in the non-randomized study. In our example 5 
treatments are included. 
tNRS: a vector with the treatments included in the non-randomized study.  
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yobs: a vector with the relative treatment effect estimates from the observational 
study, for all other treatments vs the treatment indicated in tNRS[1]. In our example 
yobs has 4 elements.  
s11, s22, s33, s44, s12, s13, s14, s23, s24, s34: the within-trial variance-covariance 
matrix corresponding to yobs. In our example this matrix is 4 × 4. 
8.1 Naïve analysis 
model{ 
for(i in 1:ns){  
### modeling the dependency between age (corresponding to data 
agedur[i,1]) and duration of illness (agedur[i,2]) in order to 
include studies with missing data on these covariates and also the 
correlation between the covariates 
agedur[i,1:2]~dmnorm(mu[1:2],prect[1:2,1:2])}  
mu[1]<-0  ### We have standardized the value of the covariates, thus 
they are centered on zero. 
mu[2]<-0 
tau1<-1 ### due to standardization of covariates 
tau2<-1 ### due to standardization of covariates 
rho~dunif(-1,1) 
T[1,1]<-tau1*tau1 
T[2,2]<-tau2*tau2 
T[1,2]<-rho*tau1*tau2 
T[2,1]<-T[1,2] 
prect[1:2,1:2]<-inverse(T[1:2,1:2]) ### due to standardization 
for(i in 1:ns){  
w[i,1] <-0 
delta1[i,t[i,1]]<-0 
u[i] ~ dnorm(0,.0001)                                          
   
for (k in 1:na[i])  {  
  se[i,t[i,k]]<-sd[i,t[i,k]]/sqrt(n[i,t[i,k]]) 
  var[i,t[i,k]]<-se[i,t[i,k]]*se[i,t[i,k]] 
  prec[i,t[i,k]]<-1/var[i,t[i,k]] 
###normal likelihood 
  y[i,t[i,k]]~dnorm(phi[i,t[i,k]],prec[i,t[i,k]]) 
phi[i,t[i,k]]<-(u[i]+delta1[i,t[i,k]])*pooled.sd[i]  
###nominator for the pooled sd   
nom1[i,k]<-n[i,t[i,k]]*sd[i,t[i,k]]*sd[i,t[i,k]] }                                              
  ss[i]<-sum(n[i,1:nt])-nt+na[i] #total sample size in a 
study 
  nom[i]<-sum(nom1[i,1:na[i]])#nominator for the pooled sd 
  pooled.sd[i]<-sqrt(nom[i]/(ss[i]-na[i]))#pooled sd 
for (k in 2:na[i]) { 
smd[i,k]<-(y[i,t[i,k]]-y[i,t[i,1]])/pooled.sd[i] 
varSMD[i,k]<-
1/n[i,t[i,k]]+1/n[i,t[i,1]]+pow(smd[i,k],2)/(2*(n[i,t[i,k
]]+n[i,t[i,1]]-2)) 
seSMD[i,k]<-sqrt(varSMD[i,k]) 
I[i,k]<-equals(t[i,1],regress.ref)-
equals(t[i,k],regress.ref)}  ### checks whether or not 
the comparison is vs placebo 
for (k in 2:na[i]) { 
delta1[i,t[i,k]]<-
delta[i,t[i,k]]+I[i,k]*beta*(agedur[i,1])+I[i,k]*gamma*(a
gedur[i,2]) #regression on age and duration of illness 
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  delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]], PRECd[i,t[i,k]])  
md[i,t[i,k]] <-  d[t[i,k]] - d[t[i,1]]  + sw[i,k]                    
PRECd[i,t[i,k]]<-1/(taud[i,t[i,k]]*taud[i,t[i,k]] )    
taud[i,t[i,k]] <- tau *2*(k-1)/k                                     
w[i,k] <- (delta[i,t[i,k]]  - d[t[i,k]] + d[t[i,1]])    
#adjustment, multi-arm RCTs 
            sw[i,k] <-sum(w[i,1:k-1])/(k-1) }}    
 
beta~dnorm(0,0.1) #regression coefficient for mean age 
gamma~dnorm(0,0.1)#regression coefficient for mean duration of 
illness 
 
### including the non-randomized study 
yobs[1:4]~dmnorm(dobs[1:4], PrecObs[1:4,1:4]) 
dobs[1:4]~dmnorm(mdobs[1:4], PrecTauObs[1:4, 1:4]) 
### we do not include regression terms here because we have assumed 
modifications of relative treatment effects only vs. placebo; the 
non-randomized study in our example only includes active drugs.   
for (i in 1:4){ 
mdobs[i]<-d[tNRS[i+1]]-d[tNRS[1]]} 
Sobs[1,1]<-s11 
Sobs[2,2]<-s22 
Sobs[3,3]<-s33 
Sobs[4,4]<-s44 
Sobs[1,2]<-s12 
Sobs[2,1]<-s12 
Sobs[1,3]<-s13 
Sobs[3,1]<-s13 
Sobs[1,4]<-s14 
Sobs[4,1]<-s14 
Sobs[2,3]<-s32 
Sobs[3,2]<-s23 
Sobs[2,4]<-s24 
Sobs[4,2]<-s24 
Sobs[4,3]<-s34 
Sobs[3,4]<-s34 
PrecObs[1:4,1:4]<-inverse(Sobs[1:4,1:4]) 
 
TauObs[1,1]<-tau.obs*tau.obs 
TauObs[2,2]<-tau.obs*tau.obs 
TauObs[3,3]<-tau.obs*tau.obs 
TauObs[4,4]<-tau.obs*tau.obs 
TauObs[1,2]<-tau.obs*tau.obs/2 
TauObs[2,1]<-tau.obs*tau.obs/2 
TauObs[1,3]<-tau.obs*tau.obs/2 
TauObs[3,1]<-tau.obs*tau.obs/2 
TauObs[1,4]<-tau.obs*tau.obs/2 
TauObs[4,1]<-tau.obs*tau.obs/2 
TauObs[2,3]<-tau.obs*tau.obs/2 
TauObs[3,2]<-tau.obs*tau.obs/2 
TauObs[2,4]<-tau.obs*tau.obs/2 
TauObs[4,2]<-tau.obs*tau.obs/2 
TauObs[3,4]<-tau.obs*tau.obs/2 
TauObs[4,3]<-tau.obs*tau.obs/2 
tau.obs<-tau 
PrecTauObs[1:4,1:4]<-inverse(TauObs[1:4,1:4]) 
 
d[ref]<-0 
for (k in 1:(ref-1)){d[k] ~ dnorm(0,.0001) }          
for (k in (ref+1):nt){d[k] ~ dnorm(0,.0001) }          
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tau~dunif(0,5) #vague prior for random effects standard deviation  
### Collection of results 
### pairwise SMDs for all comparisons 
for (c in 1:nt) {  for (k in 1:nt)  { SMD[c,k] <- d[c] - d[k]  }  } 
#compared to reference 
for (c in 1:nt) {  SMD.ref[c] <-d[c] - d[ref] } 
 
#estimating the SUCRA values 
for(k in 1:nt) { 
 order[k]<- rank(d[],k) # this is when the outcome is positive - 
omit  'nt+1-' when the outcome is negative 
 most.effective[k]<-equals(order[k],1) 
 for(j in 1:nt) {effectiveness[k,j]<- equals(order[k],j)}} 
for(k in 1:nt) { 
 for(j in 1:nt) { 
cumeffectiveness[k,j]<- sum(effectiveness[k,1:j])}} 
for(k in 1:nt) {SUCRA[k]<- sum(cumeffectiveness[k,1:(nt-1)]) /(nt-1) 
 }}}   
8.2 Using non-randomized evidence as prior information 
model{ 
for(i in 1:ns){  
### modeling the dependency between age (corresponding to data 
agedur[i,1]) and duration of illness (agedur[i,2]) in order to 
include studies with missing data on these covariates and also the 
correlation between the covariates 
agedur[i,1:2]~dmnorm(mu[1:2],prect[1:2,1:2])}  
mu[1]<-0  ### We have standardized the value of the covariates, thus 
they are centered on zero. 
mu[2]<-0 
tau1<-1 ### due to standardization 
tau2<-1 ### due to standardization 
rho~dunif(-1,1) 
T[1,1]<-tau1*tau1 
T[2,2]<-tau2*tau2 
T[1,2]<-rho*tau1*tau2 
T[2,1]<-T[1,2] 
prect[1:2,1:2]<-inverse(T[1:2,1:2]) ### due to standardization 
for(i in 1:ns){  
w[i,1] <-0 
delta1[i,t[i,1]]<-0 
u[i] ~ dnorm(0,.0001)                                          
   
for (k in 1:na[i])  {  
  se[i,t[i,k]]<-sd[i,t[i,k]]/sqrt(n[i,t[i,k]]) 
  var[i,t[i,k]]<-se[i,t[i,k]]*se[i,t[i,k]] 
  prec[i,t[i,k]]<-1/var[i,t[i,k]] 
###normal likelihood 
  y[i,t[i,k]]~dnorm(phi[i,t[i,k]],prec[i,t[i,k]]) 
phi[i,t[i,k]]<-(u[i]+delta1[i,t[i,k]])*pooled.sd[i]  
###nominator for the pooled sd   
nom1[i,k]<-n[i,t[i,k]]*sd[i,t[i,k]]*sd[i,t[i,k]] }                                              
  ss[i]<-sum(n[i,1:nt])-nt+na[i] #total sample size in a 
study 
  nom[i]<-sum(nom1[i,1:na[i]])#nominator for the pooled sd 
  pooled.sd[i]<-sqrt(nom[i]/(ss[i]-na[i]))#pooled sd 
for (k in 2:na[i]) { 
smd[i,k]<-(y[i,t[i,k]]-y[i,t[i,1]])/pooled.sd[i] 
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varSMD[i,k]<-
1/n[i,t[i,k]]+1/n[i,t[i,1]]+pow(smd[i,k],2)/(2*(n[i,t[i,k
]]+n[i,t[i,1]]-2)) 
seSMD[i,k]<-sqrt(varSMD[i,k]) 
I[i,k]<-equals(t[i,1],regress.ref)-
equals(t[i,k],regress.ref)}  ### checks whether or not 
the comparison is vs placebo 
for (k in 2:na[i]) { 
delta1[i,t[i,k]]<-
delta[i,t[i,k]]+I[i,k]*beta*(agedur[i,1])+I[i,k]*gamma*(a
gedur[i,2]) #regression on age and duration of illness 
  delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]], PRECd[i,t[i,k]])  
md[i,t[i,k]] <-  d[t[i,k]] - d[t[i,1]]  + sw[i,k]                    
PRECd[i,t[i,k]]<-1/(taud[i,t[i,k]]*taud[i,t[i,k]] )    
taud[i,t[i,k]] <- tau *2*(k-1)/k                                     
w[i,k] <- (delta[i,t[i,k]]  - d[t[i,k]] + d[t[i,1]])    
#adjustment, multi-arm RCTs 
            sw[i,k] <-sum(w[i,1:k-1])/(k-1) }}    
 
beta~dnorm(0,0.1) #regression coefficient for mean age 
gamma~dnorm(0,0.1)#regression coefficient for mean duration of 
illness 
 
###################################################### 
### formulating informative priors based on the observational 
estimates 
yobs[1:4]~dmnorm(d.obs[1:4], PrecObs[1:4,1:4]) 
### we do not include regression terms here because we have assumed 
modifications of relative treatment effects only vs. placebo; the 
non-randomized study in our example only includes active drugs.   
 
Sobs[1,1]<-s11/ww+tau.naive*tau.naive 
Sobs[2,2]<-s22/ww+tau.naive*tau.naive 
Sobs[3,3]<-s33/ww+tau.naive*tau.naive 
Sobs[4,4]<-s44/ww+tau.naive*tau.naive 
Sobs[1,2]<-s12/ww+tau.naive*tau.naive/2 
Sobs[2,1]<-s12/ww+tau.naive*tau.naive/2 
Sobs[1,3]<-s13/ww+tau.naive*tau.naive/2 
Sobs[3,1]<-s13/ww+tau.naive*tau.naive/2 
Sobs[1,4]<-s14/ww+tau.naive*tau.naive/2 
Sobs[4,1]<-s14/ww+tau.naive*tau.naive/2 
Sobs[2,3]<-s32/ww+tau.naive*tau.naive/2 
Sobs[3,2]<-s23/ww+tau.naive*tau.naive/2 
Sobs[2,4]<-s24/ww+tau.naive*tau.naive/2 
Sobs[4,2]<-s24/ww+tau.naive*tau.naive/2 
Sobs[4,3]<-s34/ww+tau.naive*tau.naive/2 
Sobs[3,4]<-s34/ww+tau.naive*tau.naive/2 
PrecObs[1:4,1:4]<-inverse(Sobs[1:4,1:4]) 
 
tau.naive<-0.085 
ww~dunif(0,0.3) ### this is used to down-weight observational 
evidence 
 
d.obs[1]~dnorm(0,.0001) 
d.obs[2]~dnorm(0,.0001) 
d.obs[3]~dnorm(0,.0001) 
d.obs[4]~dnorm(0,.0001) 
### the relative effect estimates from the observational study.  
d[4]<-d.obs[1] 
d[5]<-d.obs[2] 
d[6]<-d.obs[3] 
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d[15]<-d.obs[4] 
 
d[ref]<-0 
 
for (k in 2:3){d[k] ~ dnorm(0,.0001)} ### here we assign 
uninformative priors to the basic parameters not informed by the 
observational evidence 
  for (k in 7:14){d[k] ~ dnorm(0,.0001) }  
   d[16] ~ dnorm(0,.0001) 
tau~dunif(0,5) #vague prior for random effects standard deviation  
### Collection of results 
### pairwise SMDs for all comparisons 
for (c in 1:nt) {  for (k in 1:nt)  { SMD[c,k] <- d[c] - d[k]  }  } 
#compared to reference 
for (c in 1:nt) {  SMD.ref[c] <-d[c] - d[ref] } 
#estimating the SUCRA values 
for(k in 1:nt) { 
 order[k]<- rank(d[],k) # this is when the outcome is positive - 
omit  'nt+1-' when the outcome is negative 
 most.effective[k]<-equals(order[k],1) 
 for(j in 1:nt) {effectiveness[k,j]<- equals(order[k],j)}} 
for(k in 1:nt) { 
 for(j in 1:nt) { 
cumeffectiveness[k,j]<- sum(effectiveness[k,1:j])}} 
for(k in 1:nt) {SUCRA[k]<- sum(cumeffectiveness[k,1:(nt-1)]) /(nt-1) 
 }}} 
 
8.3 Three-level hierarchical model (C1) 
Data required: as before, but now the number of studies per design need to be also 
included in the dataset, ns1, ns2, ns3, ns4 etc.. Also the data from the studies in the 
structures y, sd, t, etc. need to be ordered per design. E.g. in y the first ns1 studies are 
of design 1, the next ns2 studies are design 2, etc. In this example we have 4 designs 
(hig RoB RCTs, unclear RoB RCTs, low RoB RCTs and NRS)  
  
model{ 
for(i in 1:ns){agedur[i,1:2]~dmnorm(mu[1:2],prect[1:2,1:2])} ###  
modelling the dependency between age (agedur[i,1]) and duration of 
illness (agedur[i,2]) in order to include studies with missing data 
on these covariates 
 
mu[1]<-0 
mu[2]<-0 
tau1<-1 
tau2<-1 
rho~dunif(-1,1) 
T[1,1]<-tau1*tau1 
T[2,2]<-tau2*tau2 
T[1,2]<-rho*tau1*tau2 
T[2,1]<-T[1,2] 
prect[1:2,1:2]<-inverse(T[1:2,1:2]) 
 
#### type 1 RCTs (high RoB) 
for(i in 1:ns1){  
w[i,1] <-0 
delta1[i,t[i,1]]<-0 
      u[i] ~ dnorm(0,.0001)                                          
  for (k in 1:na[i]){  
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se[i,t[i,k]]<-sd[i,t[i,k]]/sqrt(n[i,t[i,k]]) 
var[i,t[i,k]]<-se[i,t[i,k]]*se[i,t[i,k]] 
prec[i,t[i,k]]<-1/var[i,t[i,k]] 
#normal likelihood 
y[i,t[i,k]]~dnorm(phi[i,t[i,k]],prec[i,t[i,k]]) 
phi[i,t[i,k]]<-(u[i]+delta1[i,t[i,k]])*pooled.sd[i] 
 
#calculate the pooled SD 
nom1[i,k]<-n[i,t[i,k]]*sd[i,t[i,k]]*sd[i,t[i,k]] 
}#nominator for the pooled  sd                                              
 ss[i]<-sum(n[i,1:nt])-nt+na[i] #total sample size in a study 
nom[i]<-sum(nom1[i,1:na[i]])#nominator for the pooled  sd 
pooled.sd[i]<-sqrt(nom[i]/(ss[i]-na[i]))# pooled  sd 
for (k in 2:na[i]) { 
smd[i,k]<-(y[i,t[i,k]]-y[i,t[i,1]])/pooled.sd[i] 
varSMD[i,k]<-
1/n[i,t[i,k]]+1/n[i,t[i,1]]+pow(smd[i,k],2)/(2*(n[i
,t[i,k]]+n[i,t[i,1]]-2)) 
seSMD[i,k]<-sqrt(varSMD[i,k]) 
I[i,k]<-equals(t[i,1],3)-equals(t[i,k],3)  ### 
checks whether or not the comparison is with placebo 
} 
   for (k in 2:na[i]) { 
delta1[i,t[i,k]]<-delta[i,t[i,k]] 
+I[i,k]*beta*(agedur[i,1])+I[i,k]*gamma*(agedur[i,2])  
delta[i,t[i,k]] ~ 
dnorm(md[i,t[i,k]],taud.I[i,t[i,k]])             # 
trial-specific LOR distributions 
md[i,t[i,k]] <-  dRCT.I[t[i,k]] - dRCT.I[t[i,1]]  + 
sw[i,k]   
         
taud.I[i,t[i,k]] <- tau.I *2*(k-1)/k                                    
w[i,k] <- (delta[i,t[i,k]]  - dRCT.I[t[i,k]] + 
dRCT.I[t[i,1]]) #adjustment, multi-arm RCTs           
                sw[i,k] <-sum(w[i,1:k-1])/(k-1) } # cumulative 
adjustment for multi-arm trials                 
  }    
 
SD.I~dnorm(0,1)I(0,) #vague prior for random effects standard 
deviation                                     
tau.I<-1/(SD.I*SD.I) 
 
 
#### type II RCTs (unclear RoB) 
for(i in (ns1+1):(ns1+ns2)){ 
w[i,1] <-0 
      delta1[i,t[i,1]]<-0 
      u[i] ~ dnorm(0,.0001)                                          
for (k in 1:na[i])  {  
se[i,t[i,k]]<-sd[i,t[i,k]]/sqrt(n[i,t[i,k]]) 
var[i,t[i,k]]<-se[i,t[i,k]]*se[i,t[i,k]] 
prec[i,t[i,k]]<-1/var[i,t[i,k]] 
    
#normal likelihood 
y[i,t[i,k]]~dnorm(phi[i,t[i,k]],prec[i,t[i,k]]) 
phi[i,t[i,k]]<-(u[i]+delta1[i,t[i,k]])*pooled.sd[i] 
#calculate the pooled SD 
nom1[i,k]<-n[i,t[i,k]]*sd[i,t[i,k]]*sd[i,t[i,k]] 
#nominator for the pooled  sd 
                                       
   } 
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ss[i]<-sum(n[i,1:nt])-nt+na[i] #total sample size in a 
study 
nom[i]<-sum(nom1[i,1:na[i]])#nominator for the pooled  sd 
pooled.sd[i]<-sqrt(nom[i]/(ss[i]-na[i]))# pooled  sd 
for (k in 2:na[i]) { 
smd[i,k]<-(y[i,t[i,k]]-y[i,t[i,1]])/pooled.sd[i] 
varSMD[i,k]<-
1/n[i,t[i,k]]+1/n[i,t[i,1]]+pow(smd[i,k],2)/(2*(n[i,t[i,k
]]+n[i,t[i,1]]-2)) 
seSMD[i,k]<-sqrt(varSMD[i,k]) 
I[i,k]<-equals(t[i,1],3)-equals(t[i,k],3)  ### checks 
whether or not the comparison is with placebo 
} 
for (k in 2:na[i]) { 
delta1[i,t[i,k]]<-delta[i,t[i,k]] 
+I[i,k]*beta*(agedur[i,1])+I[i,k]*gamma*(agedur[i,2
])  
delta[i,t[i,k]] ~ 
dnorm(md[i,t[i,k]],taud.II[i,t[i,k]])             # 
trial-specific LOR distributions 
md[i,t[i,k]] <-  dRCT.II[t[i,k]] - dRCT.II[t[i,1]]  
+ sw[i,k]  
       
taud.II[i,t[i,k]] <- tau.II *2*(k-1)/k                                    
w[i,k] <- (delta[i,t[i,k]]  - dRCT.II[t[i,k]] + 
dRCT.II[t[i,1]]) #adjustment, multi-arm RCTs           
sw[i,k] <-sum(w[i,1:k-1])/(k-1) } # cumulative 
adjustment for multi-arm trials                 
  }    
 
SD.II~dnorm(0,1)I(0,) #  vague prior for random effects standard 
deviation                                       
tau.II<-1/(SD.II*SD.II) 
 
#### type III RCTs (low RoB) 
for(i in (ns1+ns2+1):(ns1+ns2+ns3)){  
w[i,1] <-0 
      delta1[i,t[i,1]]<-0 
      u[i] ~ dnorm(0,.0001)                                          
for (k in 1:na[i])  {  
se[i,t[i,k]]<-sd[i,t[i,k]]/sqrt(n[i,t[i,k]]) 
var[i,t[i,k]]<-se[i,t[i,k]]*se[i,t[i,k]] 
prec[i,t[i,k]]<-1/var[i,t[i,k]] 
#normal likelihood 
y[i,t[i,k]]~dnorm(phi[i,t[i,k]],prec[i,t[i,k]]) 
phi[i,t[i,k]]<-(u[i]+delta1[i,t[i,k]])*pooled.sd[i] 
 
#calculate the pooled SD 
nom1[i,k]<-n[i,t[i,k]]*sd[i,t[i,k]]*sd[i,t[i,k]] 
#nominator for the pooled  sd 
                                        
   } 
ss[i]<-sum(n[i,1:nt])-nt+na[i] #total sample size in a 
study 
nom[i]<-sum(nom1[i,1:na[i]])#nominator for the pooled  sd 
pooled.sd[i]<-sqrt(nom[i]/(ss[i]-na[i]))# pooled  sd 
 
 
for (k in 2:na[i]) { 
smd[i,k]<-(y[i,t[i,k]]-y[i,t[i,1]])/pooled.sd[i] 
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varSMD[i,k]<-
1/n[i,t[i,k]]+1/n[i,t[i,1]]+pow(smd[i,k],2)/(2*(n[i,t[i,k
]]+n[i,t[i,1]]-2)) 
seSMD[i,k]<-sqrt(varSMD[i,k]) 
I[i,k]<-equals(t[i,1],3)-equals(t[i,k],3)  ### checks 
whether or not the comparison is with placebo 
} 
  for (k in 2:na[i]) { 
delta1[i,t[i,k]]<-delta[i,t[i,k]] 
+I[i,k]*beta*(agedur[i,1])+I[i,k]*gamma*(agedur[i,2])  
   delta[i,t[i,k]] ~ dnorm(md[i,t[i,k]],taud.II[i,t[i,k]])              
 
md[i,t[i,k]] <-  dRCT.III[t[i,k]] - dRCT.III[t[i,1]]  + 
sw[i,k]   
         
taud.II[i,t[i,k]] <- tau.II *2*(k-1)/k                                    
w[i,k] <- (delta[i,t[i,k]]  - dRCT.III[t[i,k]] + 
dRCT.III[t[i,1]])          #adjustment, multi-arm RCTs 
            sw[i,k] <-sum(w[i,1:k-1])/(k-1) } # cumulative adjustment 
for multi-arm trials                 
  }                    
#  same tau as type II studies  
 
 
### PRIORS 
beta~dnorm(0,0.1) # priors for regression coefficients 
gamma~dnorm(0,0.1) # priors for regression coefficients 
 
dRCT.I[1]<-0 
dRCT.II[1]<-0 
dRCT.III[1]<-0 
d.NRS[1]<-0 
m.overall[1]<-0 
for (k in 2:nt){ 
dRCT.I[k] ~ dnorm(m.overall[k],prec.design)     
dRCT.II[k] ~ dnorm(m.overall[k],prec.design)  
dRCT.III[k] ~ dnorm(m.overall[k],prec.design)  
d.NRS[k] ~ dnorm(m.overall[k],prec.design) }   
  for (k in 2:nt){m.overall[k]~ dnorm(0,.001) } 
prec.design<-1/tau.sq.design 
tau.sq.design<-tau.design*tau.design 
tau.design~dnorm(0,1)I(0,)   
  
#### NRS 
y.NRS[1:4]~dmnorm(theta.NRS[1:4], Prec.NRS[1:4,1:4])  ### likelihood 
of the single NRS study 
theta.NRS[1:4]~dmnorm(eff.NRS[1:4], Prec.T.NRS[1:4,1:4]) ### Random 
effects 
 
eff.NRS[1]<-d.NRS[4] 
eff.NRS[2]<-d.NRS[5] 
eff.NRS[3]<-d.NRS[6] 
eff.NRS[4]<-d.NRS[15] 
 
 
ww<-1 ### variance inflation factor 
 
S.NRS[1,1]<-s11/ww 
S.NRS[2,2]<-s22/ww 
S.NRS[3,3]<-s33/ww 
S.NRS[4,4]<-s44/ww 
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S.NRS[1,2]<-s12/ww 
S.NRS[2,1]<-s12/ww 
S.NRS[1,3]<-s13/ww 
S.NRS[3,1]<-s13/ww 
S.NRS[1,4]<-s14/ww 
S.NRS[4,1]<-s14/ww 
S.NRS[2,3]<-s32/ww 
S.NRS[3,2]<-s23/ww 
S.NRS[2,4]<-s24/ww 
S.NRS[4,2]<-s42/ww 
S.NRS[4,3]<-s34/ww 
S.NRS[3,4]<-s34/ww 
Prec.NRS[1:4,1:4]<-inverse(S.NRS[1:4,1:4]) 
 
 
T.NRS[1,1]<-SD.I*SD.I 
T.NRS[2,2]<-SD.I*SD.I 
T.NRS[3,3]<-SD.I*SD.I 
T.NRS[4,4]<-SD.I*SD.I 
T.NRS[1,2]<-SD.I*SD.I/2 
T.NRS[2,1]<-SD.I*SD.I/2 
T.NRS[1,3]<-SD.I*SD.I/2 
T.NRS[3,1]<-SD.I*SD.I/2 
T.NRS[1,4]<-SD.I*SD.I/2 
T.NRS[4,1]<-SD.I*SD.I/2 
T.NRS[2,3]<-SD.I*SD.I/2 
T.NRS[3,2]<-SD.I*SD.I/2 
T.NRS[2,4]<-SD.I*SD.I/2 
T.NRS[4,2]<-SD.I*SD.I/2 
T.NRS[4,3]<-SD.I*SD.I/2 
T.NRS[3,4]<-SD.I*SD.I/2 
Prec.T.NRS[1:4,1:4]<-inverse(T.NRS[1:4,1:4]) 
 
 
 
# Collection of results########### 
# pairwise SMDs 
# for all comparisons 
for (c in 1:nt) {   
for (k in 1:nt)   
{ SMD[c,k] <- m.overall[c] - m.overall[k]  }  } 
#compared to baseline 
for (c in 1:nt) {  SMD.ref[c] <-m.overall[c] - m.overall[ref] }  
}}}}}   
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